<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antithrombin III for critically ill patients - Allingstrup, M - 2016 | Cochrane Library</title> <meta content="Antithrombin III for critically ill patients - Allingstrup, M - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005370.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antithrombin III for critically ill patients - Allingstrup, M - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005370.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005370.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antithrombin III for critically ill patients" name="citation_title"/> <meta content="Mikkel Allingstrup" name="citation_author"/> <meta content="mikkel.allingstrup@gmail.com" name="citation_author_email"/> <meta content="Jørn Wetterslev" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Frederikke B Ravn" name="citation_author"/> <meta content="Rigshospitalet" name="citation_author_institution"/> <meta content="Ann Merete Møller" name="citation_author"/> <meta content="Herlev and Gentofte Hospital, University of Copenhagen" name="citation_author_institution"/> <meta content="Arash Afshari" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD005370.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005370.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005370.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005370.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents [adverse effects, *therapeutic use]; Anticoagulants [adverse effects, *therapeutic use]; Antithrombin III [adverse effects, *therapeutic use]; Critical Illness [*mortality]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005370.pub3&amp;doi=10.1002/14651858.CD005370.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005370\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005370\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005370.pub3",title:"Antithrombin III for critically ill patients",firstPublishedDate:"Feb 9, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005370.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005370.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005370.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005370.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005370.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005370.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005370.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005370.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005370.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005370.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2274 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005370.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/appendices#CD005370-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/table_n/CD005370StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/table_n/CD005370StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antithrombin III for critically ill patients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mikkel Allingstrup</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-cr-0003">Jørn Wetterslev</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-cr-0004">Frederikke B Ravn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-cr-0005">Ann Merete Møller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-cr-0006">Arash Afshari</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information/en#CD005370-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005370.pub3">https://doi.org/10.1002/14651858.CD005370.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005370-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005370-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005370-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005370-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005370-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005370-abs-0001" lang="en"> <section id="CD005370-sec-0001"> <h3 class="title" id="CD005370-sec-0001">Background</h3> <p>Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti‐inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown. This review was published in 2008 and updated in 2015. </p> </section> <section id="CD005370-sec-0002"> <h3 class="title" id="CD005370-sec-0002">Objectives</h3> <p>To examine:</p> <p>1. The effect of AT III on mortality in critically ill participants.</p> <p>2. The benefits and harms of AT III.</p> <p>We investigated complications specific and not specific to the trial intervention, bleeding events, the effect on sepsis and disseminated intravascular coagulation (DIC) and the length of stay in the intensive care unit (ICU) and in hospital in general. </p> </section> <section id="CD005370-sec-0003"> <h3 class="title" id="CD005370-sec-0003">Search methods</h3> <p>We searched the following databases from inception to 27 August 2015: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), EMBASE (Ovid SP,), CAB, BIOSIS and CINAHL. We contacted the main authors of trials to ask for any missed, unreported or ongoing trials. </p> </section> <section id="CD005370-sec-0004"> <h3 class="title" id="CD005370-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published, or language. We contacted the investigators and the trial authors in order to retrieve missing data. In this updated review we include trials only published as abstracts. </p> </section> <section id="CD005370-sec-0005"> <h3 class="title" id="CD005370-sec-0005">Data collection and analysis</h3> <p>Our primary outcome measure was mortality. Two authors each independently abstracted data and resolved any disagreements by discussion. We presented pooled estimates of the intervention effects on dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CI). We performed subgroup analyses to assess risk of bias, the effect of AT III in different populations (sepsis, trauma, obstetrics, and paediatrics), and the effect of AT III in patients with or without the use of concomitant heparin. We assessed the adequacy of the available number of participants and performed trial sequential analysis (TSA) to establish the implications for further research. </p> </section> <section id="CD005370-sec-0006"> <h3 class="title" id="CD005370-sec-0006">Main results</h3> <p>We included 30 RCTs with a total of 3933 participants (3882 in the primary outcome analyses). </p> <p>Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality with a RR of 0.95 (95% CI 0.88 to 1.03), I² statistic = 0%, fixed‐effect model, 29 trials, 3882 participants, <i>moderate quality of evidence</i>). For trials with low risk of bias the RR was 0.96 (95% Cl 0.88 to 1.04, I² statistic = 0%, fixed‐effect model, 9 trials, 2915 participants) and for high risk of bias RR 0.94 (95% Cl 0.77 to 1.14, I² statistic = 0%, fixed‐effect model, 20 trials, 967 participants). </p> <p>For participants with severe sepsis and DIC the RR for mortality was non‐significant, 0.95 (95% Cl 0.88 to 1.03, I² statistic = 0%, fixed‐effect model, 12 trials, 2858 participants, <i>moderate quality of evidence</i>). </p> <p>We conducted 14 subgroup and sensitivity analyses with respect to the different domains of risk of bias, but detected no statistically significant benefit in any subgroup analyses. </p> <p>Our secondary objective was to assess the benefits and harms of AT III. For complications specific to the trial intervention the RR was 1.26 (95% Cl 0.83 to 1.92, I² statistic = 0%, random‐effect model, 3 trials, 2454 participants, <i>very low quality of evidence</i> ). For complications not specific to the trial intervention, the RR was 0.71 (95% Cl 0.08 to 6.11, I² statistic = 28%, random‐effects model, 2 trials, 65 participants, <i>very low quality of evidence</i> ). For complications other than bleeding, the RR was 0.72 ( 95% Cl 0.42 to 1.25, I² statistic = 0%, fixed‐effect model, 3 trials, 187 participants, <i>very low quality of evidence</i> ). Eleven trials investigated bleeding events and we found a statistically significant increase, RR 1.58 (95% CI 1.35 to 1.84, I² statistic = 0%, fixed‐effect model, 11 trials, 3019 participants, <i>moderate quality of evidence</i> ) in the AT III group. The amount of red blood cells administered had a mean difference (MD) of 138.49 (95% Cl ‐391.35 to 668.34, I² statistic = 84%, random‐effect model, 4 trials, 137 participants, <i>very low quality of evidence</i> ). The effect of AT III in patients with multiple organ failure (MOF) was a MD of ‐1.24 (95% Cl ‐2.18 to ‐0.29, I² statistic = 48%, random‐effects model, 3 trials, 156 participants, <i>very low quality of evidence</i> ) and for patients with an Acute Physiology and Chronic Health Evaluation score (APACHE) at II and III the MD was ‐2.18 (95% Cl ‐4.36 to ‐0.00, I² statistic = 0%, fixed‐effect model, 3 trials, 102 participants, <i>very low quality of evidence</i> ). The incidence of respiratory failure had a RR of 0.93 (95% Cl 0.76 to 1.14, I² statistic = 32%, random‐effects model, 6 trials, 2591 participants, <i>moderate quality of evidence</i> ). AT III had no statistically significant impact on the duration of mechanical ventilation (MD 2.20 days, 95% Cl ‐1.21 to 5.60, I² statistic = 0%, fixed‐effect model, 3 trials, 190 participants, <i>very low quality of evidence</i> ); on the length of stay in the ICU (MD 0.24, 95% Cl ‐1.34 to 1.83, I² statistic = 0%, fixed‐effect model, 7 trials, 376 participants, <i>very low quality of evidence</i> ) or on the length of stay in hospital in general (MD 1.10, 95% Cl ‐7.16 to 9.36), I² statistic = 74%, 4 trials, 202 participants, <i>very low quality of evidence</i>). </p> </section> <section id="CD005370-sec-0007"> <h3 class="title" id="CD005370-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence to support AT III substitution in any category of critically ill participants including the subset of patients with sepsis and DIC. We did not find a statistically significant effect of AT III on mortality, but AT III increased the risk of bleeding events. Subgroup analyses performed according to duration of intervention, length of follow‐up, different patient groups, and use of adjuvant heparin did not show differences in the estimates of intervention effects. The majority of included trials were at high risk of bias (GRADE; very low quality of evidence for most of the analyses). Hence a large RCT of AT III is needed, without adjuvant heparin among critically ill patients such as those with severe sepsis and DIC, with prespecified inclusion criteria and good bias protection. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005370-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005370-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005370-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005370-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005370-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005370-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005370-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005370-abs-0004" lang="en"> <h3>Antithrombin III for critically ill patients</h3> <p><b>Background</b> </p> <p>Antithrombin is a small particle produced by the liver. It deactivates several substances which affect the ability of the blood to form clots. Its activity is increased many‐fold by the drug heparin, which enhances the binding of antithrombin to clotting factors so that the blood does not form clots. Antithrombin also reduces inflammation in the human body. Inflammation is the body's attempt at self protection to remove harmful stimuli and begin healing processes. Inflammation is thus not always a bad process. </p> <p>This updated review assessed the effects of antithrombin in people recovering from critical illness. Our primary goal was to investigate whether the number of people who died changed by giving antithrombin. We also investigated whether there were more complications among people treated with this drug, the extent of bleeding and the amount of blood given to the critical ill people. Finally we examined the impact of antithrombin on the duration of respiratory therapy, length of stay in the intensive care units and in the hospital in general. </p> <p><b>Study characteristics</b> </p> <p>We included 30 trials with 3933 participants (3882 in our data calculation) in this updated review. We found the overall quality of trials to be poor, with little information on how the experiments were carried out. The results were limited and the included trials were mostly small. In most trials, there was a high risk of misleading information. Thus, the results must be interpreted with caution. The evidence is up to date to 27 August 2015. </p> <p><b>Study funding sources</b> </p> <p>Three of the 30 included trials reported receiving money from drug companies.</p> <p><b>Key results</b> </p> <p>In our review we could not identify a clear advantage of antithrombin for the objectives we examined, overall or among various types of patients or subgroups. In our investigation of bleeding events, however, we found an increased risk of bleeding for patients treated with antithrombin. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, there was a low quality of information from the studies regarding all of the results. We conclude that there is a need for a large‐scale clinical trial with low risk of misleading information to investigate the advantages and harms of this drug among critically ill patients. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005370-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005370-sec-0101"></div> <h3 class="title" id="CD005370-sec-0102">Implications for practice</h3> <section id="CD005370-sec-0102"> <p>There is insufficient evidence to support AT III substitution in any category of critically ill people. We did not find a statistically significant effect of AT III on mortality, but AT III increased the risk of bleeding events. Subgroup analyses performed according to duration of intervention, length of follow‐up, different patient groups, and use of adjuvant heparin did not show differences in the estimates of intervention effects. Serious methodological shortcomings of the included studies are, however, likely to have influenced the overall intervention effect (<a href="./full#CD005370-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Trial sequential analysis showed that there is sufficient evidence to reject a beneficial effect of more than 10% RRR (4% absolute risk reduction) on overall mortality and for trials including participants with sepsis and DIC. There also remains the possibility that the use of AT III may be harmful. </p> <p>The GRADE approach only reaffirmed our interpretation of the level of evidence, and we are confident that at this stage the quality of evidence in regard to our primary outcomes is moderate, despite the fact that many of the trials have high risk of bias. </p> </section> <h3 class="title" id="CD005370-sec-0103">Implications for research</h3> <section id="CD005370-sec-0103"> <p>To our knowledge only one trial (<a href="./references#CD005370-bbs2-0055" title="D'angeloA , ValsecchiL . A double‐blind trial of high‐dose antithrombin supplementation in early pre‐eclampsia. Thrombosis Research2005;115(Suppl 1):117. ">D'angelo 2005</a>) is ongoing. The participants are women with pre‐eclampsia occurring before the 30th week of gestation. We have found no trials registered dealing with the effect of AT III in septic patients. </p> <p>There is a need for a large‐scale randomized controlled trial with low risk of bias to evaluate the effectiveness of AT III without heparin, before this intervention can be used routinely in critically ill patients. We recognize the heterogeneity in the patient population in the included trials and, as a consequence of the high mortality rate in the septic population, we believe that a new trial should address the effect of AT III in septic patients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005370-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005370-sec-0022"></div> <div class="table" id="CD005370-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AT III compared to control for critically ill patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Setting</b> : Worldwide<br/> <b>Intervention</b> : AT III<br/> <b>Comparison</b>: Control </p> <p><b>Patient or population</b>: critically ill participants </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with AT III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality (subgroup analysis on bias risk)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b><br/> (0.88 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3882<br/> (29 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>9 trials had low risk of bias, 20 trials high risk of bias.</p> <p>Trial sequential analysis (TSA) adjusted RR 0.95 (95% CI 0.87 to 1.04).</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (339 to 396) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>295 per 1000</b><br/> (273 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bleeding events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.58</b> (1.35 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3019<br/> (11 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6 trials had low risk of bias, 5 trials high risk of bias. Based on the TSA analysis, there seem to be evidence indicating that AT III increases risk of bleeding (<a href="./full#CD005370-fig-0001">Figure 1</a>). TSA adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (339 to 396) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/> (87 to 119) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Incidence of respiratory failure not present at admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b><br/> (0.76 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2591<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5 trials had low risk of bias, 1 trial high risk of bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/> (80 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> (241 to 361) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 2.2 more (1.21 fewer to 5.6 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials had low risk of bias, 1 trial high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay in hospital</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean length of stay in hospital in the intervention group was 1.1 more (7.16 fewer to 9.36 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials had low risk of bias, 2 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of stay in ICU</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean length of stay in ICU in the intervention group was 0.24 more (1.34 fewer to 1.83 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials had low risk of bias, 4 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall mortality among patients with severe sepsis &amp; DIC</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> </p> <p>(0.88 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2858<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,8</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4 trials had low risk of bias, 8 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b><br/> (407 to 476) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><br/> (345 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>With the exception of <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a> there was a high risk of bias in all trials. </p> <p><sup>2</sup>The entry refers to trials in <a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>. The outcome was downgraded two levels because of the substantial number of trials with high risk of bias but TSA led to an upgrade of one level to <i>moderate quality of evidence,</i> indicating no benefit for survival. The choice for this TSA upgrade was based on increased precision with continuity correction for zero event trials, adjustment for the risk of random error, a calculation of the required information size leading to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials. </p> <p><sup>3</sup>The entry refers to trials in <a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>. The outcome was downgraded from high to <i>moderate quality of evidence</i> because majority of trials had high risk of bias. </p> <p><sup>4</sup>The entry refers to trials in <a href="./references#CD005370-fig-0028" title="">Analysis 1.19</a>. The outcome was downgraded from high to <i>moderate quality of evidence</i> since one large trial provided most of the data (<a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). </p> <p><sup>5</sup>The entry refers to trials in <a href="./references#CD005370-fig-0029" title="">Analysis 1.20</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval. </p> <p><sup>6</sup>The entry refers to trials in <a href="./references#CD005370-fig-0030" title="">Analysis 1.21</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval. </p> <p><sup>7</sup>The entry refers to trials in <a href="./references#CD005370-fig-0031" title="">Analysis 1.22</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, most of them with high risk of bias. </p> <p><sup>8</sup>The entry refers to trials in <a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of numerous trials with high risk of bias. The vast majority of trials were small and poorly described. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD005370-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial sequential analysis of AT III vs placebo or no intervention on number of bleeding events. The Diversity (D‐square) is 0%, the control event proportion is 13.2% and the required information size is estimated for an anticipated relative risk increase of 20% with a type 1 and 2 error risk of 5% and 20% respectively. The cumulative Z‐curve is breaking through the trial sequential monitoring boundary for harm suggesting, even though the required information size has not been reached, that AT III increases the number of bleeding events. The TSA‐adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85)." data-id="CD005370-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of AT III vs placebo or no intervention on number of bleeding events. The Diversity (D‐square) is 0%, the control event proportion is 13.2% and the required information size is estimated for an anticipated relative risk increase of 20% with a type 1 and 2 error risk of 5% and 20% respectively. The cumulative Z‐curve is breaking through the trial sequential monitoring boundary for harm suggesting, even though the required information size has not been reached, that AT III increases the number of bleeding events. The TSA‐adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85). </p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005370-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005370-sec-0023"></div> <section id="CD005370-sec-0024"> <h3 class="title" id="CD005370-sec-0024">Description of the condition</h3> <p>Despite advances in the medical field, growing numbers of patients are becoming critically ill. Each year, 5,700,000 people in the USA are admitted to intensive care units (ICUs) (<a href="./references#CD005370-bbs2-0084" title="WunschH , AngusD , HarrisonD , CollangeO , FowlerR , HosteE , et al. Variation in critical care services across North America and Western Europe. Critical Care Medicine2008;36(10):2787‐93. [PUBMED: 18766102] ">Wunsch 2008</a>). </p> <p>Critical illness is characterized by cellular immune dysfunction, vascular damage and uncontrolled hyperinflammation, even when the cause of illness is not infection. In critical illness, a systemic activation of coagulation may occur which, at its worst, results in a fulminant disseminated intravascular coagulation (DIC). DIC is characterized by simultaneous widespread microvascular thrombosis and profuse bleeding from various sites (<a href="./references#CD005370-bbs2-0068" title="LeviM , DeJongeE , Van derPollT . New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Annals of Medicine2004;36(1):41‐9. ">Levi 2004</a>). Sepsis resulting from a generalized inflammatory and procoagulant response to an infection is associated with a high risk of mortality. Twenty per cent of patients who develop severe sepsis will die during their hospitalization (<a href="./references#CD005370-bbs2-0069" title="MayrF , YendeS , AngusD . Epidemiology of severe sepsis. Virulence2014;5(1):4‐11. [PUBMED: 24335434] ">Mayr 2014</a>). Septic shock is associated with the highest mortality, approaching 50% (<a href="./references#CD005370-bbs2-0069" title="MayrF , YendeS , AngusD . Epidemiology of severe sepsis. Virulence2014;5(1):4‐11. [PUBMED: 24335434] ">Mayr 2014</a>). This rate increases in the presence of circulatory shock despite aggressive antimicrobial therapy, adequate fluid resuscitation, and optimal care (<a href="./references#CD005370-bbs2-0072" title="PeritiP . Current treatment of sepsis and endotoxaemia. Expert opinion of Pharmacotherapy2000;1(6):1203‐17. [MEDLINE: 11249488] ">Periti 2000</a>), and may reach as high as 70% in patients with multiple organ dysfunction (<a href="./references#CD005370-bbs2-0075" title="PoldermanKH , GirbesARJ . Drug intervention trials in sepsis: divergent results. Lancet2004;363(9422):1721‐3. [MEDLINE: 15158636] ">Polderman 2004</a>). </p> <p>The inflammation associated with critical illness is characterized by an increase in the number and activity of numerous molecules, such as platelet activating factor, von Willebrand factor, and tumour necrosis factor. There is a simultaneous increase in the activity of pro‐inflammatory and pro‐coagulant processes, such as thrombin formation, fibrin deposition at the vascular wall, and the formation of aggregates containing platelets and leukocytes. Leukocyte rolling, adhesion, and transmigration are also important parts of the inflammatory reaction. These processes lead to capillary leakage, severe disturbance of the microcirculation, tissue damage, and eventually multiorgan failure and death (<a href="./references#CD005370-bbs2-0057" title="BeckerBF , HeindlB , KupattC , ZahlerS . Endothelial function and hemostasis. Zeitschrift fur Kardiologie2000;89(3):160‐7. [MEDLINE: 10798271] ">Becker 2000</a>). </p> </section> <section id="CD005370-sec-0025"> <h3 class="title" id="CD005370-sec-0025">Description of the intervention</h3> <p>Any proposed treatment of critical illness should aim to eliminate the underlying disorder or condition and to restore microvascular function, hence reducing organ dysfunction (<a href="./references#CD005370-bbs2-0068" title="LeviM , DeJongeE , Van derPollT . New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Annals of Medicine2004;36(1):41‐9. ">Levi 2004</a>). </p> <p>Antithrombin III (AT III) is primarily a potent anticoagulant with independent anti‐inflammatory properties. AT III irreversibly inhibits serine proteases (for example, activated factor X and thrombin) in a one‐to‐one ratio, with the generation of protease‐AT III complexes. Heparin prevents AT III from interacting with the endothelial cell surface by binding to sites on the AT III molecule, competing for the AT III binding site, and reducing AT III ability to interact with its cellular receptor. AT III's anticoagulant effect is thus greatly accelerated (by a factor of 1000) by heparin; heparin reduces AT III's anti‐inflammatory properties, weakens vascular protection, and increases bleeding events (<a href="./references#CD005370-bbs2-0060" title="DiazR , MoffettBS , KarabinasS , GuffreyD , MahoneyDHJr , YeeDL . Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. Journal of Pediatrics2015;167(3):645‐9. [DOI: 10.1016/j.jpeds.2015.06.006; PUBMED: 26148660] ">Diaz 2015</a>; <a href="./references#CD005370-bbs2-0070" title="OpalSM , KesslerCM , RoemischJ , KnaubS . Antithrombin, heparin, and heparan sulfate. Critical Care Medicine2002;30(5 Suppl):S325‐31. [MEDLINE: 12004255] ">Opal 2002</a>; <a href="./references#CD005370-bbs2-0077" title="RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Critical Care2002;Aug; 6(4):349‐56. [MEDLINE: 12225612] ">Rublee 2003</a>). </p> <p>Heparin in patients with sepsis, septic shock, or DIC associated with infection may be associated with decreased mortality (<a href="./references#CD005370-bbs2-0085" title="ZarychanskiR , Abou‐SettaAM , KanjiS , TurgeonAF , KumarA , HoustonDS , et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Critical Care Medicine2015;43(3):511–8. [PUBMED: 25493972] ">Zarychanski 2015</a>). However, the overall effect is still not clear. Major bleeding events related to heparin administration cannot be excluded (<a href="./references#CD005370-bbs2-0085" title="ZarychanskiR , Abou‐SettaAM , KanjiS , TurgeonAF , KumarA , HoustonDS , et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Critical Care Medicine2015;43(3):511–8. [PUBMED: 25493972] ">Zarychanski 2015</a>) and safety outcomes have yet to be validated in a multicentre trial setting. </p> </section> <section id="CD005370-sec-0026"> <h3 class="title" id="CD005370-sec-0026">How the intervention might work</h3> <p>The blood concentration of AT III falls by 20% to 40% in septic patients, and these levels correlate with disease severity and clinical outcome (<a href="./references#CD005370-bbs2-0070" title="OpalSM , KesslerCM , RoemischJ , KnaubS . Antithrombin, heparin, and heparan sulfate. Critical Care Medicine2002;30(5 Suppl):S325‐31. [MEDLINE: 12004255] ">Opal 2002</a>; <a href="./references#CD005370-bbs2-0083" title="WiedermannCJ , RömischJ . The anti‐inflammatory actions of antithrombin ‐ a review. Acta Medica Austriaca2002;29(3):89‐92. [MEDLINE: 12168569] ">Wiedermann 2002</a>). This reduction in concentration is due to the combined effect of decreased production of AT III in the liver, inactivation by the enzyme elastase, which is increased during inflammation, and loss of AT III from the circulation into tissues through inflamed and leaking capillary blood vessels. These processes reduce the half‐life of AT III from a mean of 55 hours to 20 hours (<a href="./references#CD005370-bbs2-0061" title="FourrierF , JourdainM , TournoysA . Clinical trial results with antithrombin III in sepsis. Critical Care Medicine2000;28(9 Suppl):S38‐43. [MEDLINE: 11007196] ">Fourrier 2000</a>). The main mechanism of AT III depletion in severe sepsis is linked to consumption of the molecule. </p> <p>It is this depletion of AT III that has prompted research into the potential benefits of replenishing AT III levels. Investigators have often tried to increase the antithrombin concentration to supranormal values because the activity of pro‐inflammatory and pro‐coagulant molecules are increased in critically ill patients. Thus artificially high levels of AT III may be required to overcome the inhibitory effect of thrombin and other such serine proteases. This is because the normal serum concentration of AT III does not necessarily reflect the amount bound to endothelial receptors and appears insufficient (<a href="./references#CD005370-bbs2-0061" title="FourrierF , JourdainM , TournoysA . Clinical trial results with antithrombin III in sepsis. Critical Care Medicine2000;28(9 Suppl):S38‐43. [MEDLINE: 11007196] ">Fourrier 2000</a>). Finally, by blocking the actions of thrombin, AT III may have anti‐angiogenic and antitumour properties (<a href="./references#CD005370-bbs2-0067" title="LarssonH , ÅkerudP , NordlingK , Raub‐SegallE , Claesson‐WelshL , BjorkI . A novel anti‐angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. Journal of Biological Chemistry2001;276(15):11996‐2002. [MEDLINE: 11278631] ">Larsson 2001</a>). </p> </section> <section id="CD005370-sec-0027"> <h3 class="title" id="CD005370-sec-0027">Why it is important to do this review</h3> <p>Although critically ill patients are a heterogeneous population, they are characterized by having systemic inflammation, no matter what the cause of their illness. This inflammation causes further damage to tissues and organs and can result in multiple organ failure and death. The process of inflammation can be modified by AT III, whether or not clotting is abnormal, and it is possible that AT III can reduce the high death rate or permanent damage experienced by critically ill patients. The benefit of AT III supplementation in critically ill patients is still controversial and its efficacy is still debated (<a href="./references#CD005370-bbs2-0078" title="TagamiT , MatsuiH , HoriguchiH , FushimiK , YasunagaH . Antithrombin and mortality in severe pneumonia patients with sepsis‐associated disseminated intravascular coagulation: an observational nationwide study. Journal of Thrombosis and HaemostasisSeptember 2014;12(9):1470–9. [PUBMED: 24943516] ">Tagami 2014</a>; <a href="./references#CD005370-bbs2-0079" title="TagamiT , MatsuiH , FushimiK , YasunagaH . Supplemental dose of antithrombin use in disseminated intravascular coagulation patientsafter abdominal sepsis. Thrombosis and Haemostasis2015;114(3):537‐45. [PUBMED: 25948492] ">Tagami 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005370-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005370-sec-0028"></div> <p>To examine:</p> <p> <ol id="CD005370-list-0001"> <li> <p>The effect of AT III on mortality in critically ill participants.</p> </li> <li> <p>The benefits and harms of AT III.</p> </li> </ol> </p> <p>We investigated complications specific and not specific to the trial intervention, bleeding events, the effect on sepsis and DIC and the length of stay in ICU and in hospital in general. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005370-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005370-sec-0029"></div> <section id="CD005370-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005370-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published, or language. We contacted the investigators and the authors in order to retrieve relevant data. We included unpublished trials only if trial data and methodological descriptions were either provided in written form or could be retrieved from the trial authors. We excluded cross‐over trials. We include In this updated review trials published as abstracts (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>). </p> </section> <section id="CD005370-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included critically ill participants as variously defined by the trial authors. However, we excluded trials of adjuvant AT III administration for the reduction of cardiovascular events in the invasive treatment of acute myocardial infarction. </p> <p>The terminology for sepsis, as originally proposed by the American College of Chest Physicians and the Society of Critical Care Medicine, is in many ways outdated (<a href="./references#CD005370-bbs2-0071" title="OpalSM . Clinical trial design and outcomes in patients with severe sepsis. Shock2003;20(4):295‐302. [MEDLINE: 14501941] ">Opal 2003</a>). A loose definition of sepsis can easily result in enrolment of a heterogeneous population and hence in exaggerated findings, in either direction, that are difficult to reproduce. However, we accepted the various definitions of sepsis, septic shock, DIC, and other critical illnesses as proposed by the authors; we did not exclude any trial based on their definitions. We chose to accept the term 'standard treatment of sepsis and DIC' as reported by many authors, despite the lack of a generally accepted treatment regimen. </p> <p>We classified two trials as obstetric trials (<a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>); four trials as paediatric trials (<a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>); and a further two trials as trauma trials (<a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). </p> </section> <section id="CD005370-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included AT III versus no intervention or placebo. We included any dose of AT III, any duration of administration, and co‐interventions, but excluded trials that compared different doses of AT III. </p> </section> <section id="CD005370-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD005370-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005370-list-0002"> <li> <p>Overall mortality (longest follow‐up, regardless of the period of follow‐up)</p> </li> </ol> </p> </section> <section id="CD005370-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005370-list-0003"> <li> <p>Complications during the inpatient stay specific to the trial intervention, e.g. pneumonia, congestive cardiac failure, respiratory failure, myocardial infarction, renal failure, cerebrovascular accident </p> </li> <li> <p>Complications during the inpatient stay not specific to the trial intervention, e.g. bleeding, limb venous thrombosis, line sepsis, local haematoma </p> </li> <li> <p>Complications specific to the trial intervention other than bleeding</p> </li> <li> <p>Bleeding events</p> </li> <li> <p>Amount of red blood cells administered</p> </li> <li> <p>Incidence of surgical intervention</p> </li> <li> <p>Severity of sepsis (according to different organ dysfunction scores; sepsis versus septic shock if adequately defined by authors) </p> </li> <li> <p>Incidence of respiratory failure not present at admission (mechanically‐assisted ventilation)</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Length of stay in hospital</p> </li> <li> <p>Mean length of stay in the intensive care unit (ICU)</p> </li> <li> <p>Overall mortality among patients with severe sepsis and DIC</p> </li> </ol> </p> <p>We defined bleeding events (4) as intracranial bleeding or bleeding requiring transfusion of at least three units of blood. We counted repeated transfusions in the same participant as a singular event. </p> </section> </section> </section> <section id="CD005370-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005370-sec-0038"> <h4 class="title">Electronic searches</h4> <p>In this updated review, we have further extended the original review's search from November 2006 (<a href="./references#CD005370-bbs2-0087" title="AfshariA , WetterslevJ , BrokJ , MøllerA . Antithrombin III for critically ill patients. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD005370.pub2] ">Afshari 2008</a>). Thus, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 8). We updated our search of MEDLINE (Ovid SP, to 27 August 2015), EMBASE (Ovid SP, to 27 August 2015) and CINAHL (to 27 August 2015). The search is now from inception until 27 August 2015. </p> <p>For specific information regarding our search strategies and results, please see <a href="./appendices#CD005370-sec-0107">Appendix 1</a>. </p> </section> <section id="CD005370-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched for ongoing clinical trials and unpublished trials on the following Internet sites: </p> <p> <ol id="CD005370-list-0004"> <li> <p><a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a> </p> </li> <li> <p><a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> </p> </li> <li> <p><a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a> </p> </li> </ol> </p> <p>We handsearched the reference lists of reviews, randomized and non‐randomized trials, and editorials for additional trials. We contacted the main authors of trials and experts in this field to ask for any missed, unreported, or ongoing studies. We applied no language restrictions to eligible reports. We conducted the latest search on 27 August 2015. </p> </section> </section> <section id="CD005370-sec-0040"> <h3 class="title" id="CD005370-sec-0040">Data collection and analysis</h3> <p>Three review authors (FR, MA and AA) independently screened and classified all citations as potential primary studies, review articles or other. The three review authors also independently examined all potential primary studies and decided on their inclusion in the review. We evaluated all trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention‐to‐treat analysis, funding and completeness of follow‐up) (See Figure 2; Figure 3). We assessed each trial quality factor separately and defined the trials as having low risk of bias only if they adequately fulfilled all of the criteria. We independently abstracted and evaluated methodology and outcomes from each trial, in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005370-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [DOI: 10.1002/9780470712184] ">Higgins 2011</a>). We resolved disagreements by consensus among the review authors. </p> <section id="CD005370-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We assessed the reports identified from the described searches and excluded obviously irrelevant reports. We screened all articles by title and abstract, and then as full‐text articles for inclusion. We list all excluded studies with reasons for their exclusion in the <a href="./references#CD005370-sec-0120" title="">Characteristics of excluded studies</a> </p> <p>Two review authors (FR, MA) independently examined the retrieved reports for eligibility. We performed this process without blinding to study authors, institution, journal of publication or results. We resolved disagreements by consensus among the review authors. We provide a detailed description of the search and assessment. </p> </section> <section id="CD005370-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We used the above strategy to search for relevant trials. We then screened the titles and abstracts in order to identify studies for eligibility. We independently extracted and collected the data on a standardized paper form. We were not blinded to the study author, source institution, or the publication source of trials. We resolved disagreements by discussion and approached all first authors of the included trials for additional information on risks of bias. For more detailed information please see the section <a href="#CD005370-sec-0110">Contributions of authors</a>. </p> </section> <section id="CD005370-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We evaluated the validity and design characteristics of each trial. We evaluated trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention‐to‐treat analysis, funding and completeness of follow‐up). We assessed each trial quality factor separately and defined the trials as having a low risk of bias only if they adequately fulfilled all of the criteria. </p> <p>1. Random sequence generation</p> <p>Assessment of randomization: sufficiency of the method in producing two comparable groups before intervention. </p> <p>Grade: ’low risk’: a truly random process (e.g. random computer number generator, coin tossing, throwing dice); ’high risk’: any non‐random process (e.g. date of birth, date of admission by hospital or clinic record number or by availability of the intervention); or ’unclear risk’: insufficient information. </p> <p>2. Allocation concealment</p> <p>Allocation method prevented investigators or participants from foreseeing assignment.</p> <p>Grade: ’low risk’: central allocation or sealed opaque envelopes; ’high risk’: using an open allocation schedule or other unconcealed procedure; or ’unclear risk’: insufficient information. </p> <p>3. Blinding</p> <p>Assessment of appropriate blinding of the team of investigators and participants: person responsible for participant care, participants and outcome assessors. </p> <p>Grade: ’low risk’: blinding considered adequate if participants and personnel were kept unaware of intervention allocations after inclusion of participants into the study, and if the method of blinding involved a placebo indistinguishable from the intervention, as mortality is an objective outcome; ’high risk’: not double‐blinded, categorized as an open‐label study, or without use of a placebo indistinguishable from the intervention; ’unclear risk’: blinding not described. </p> <p>4. Incomplete outcome data</p> <p>Completeness of outcome data, including attritions and exclusions.</p> <p>Grade: ’low risk’: numbers and reasons for dropouts and withdrawals in the intervention groups described, or no dropouts or withdrawals were specified; ’high risk’: no description of dropouts and withdrawals provided; ’unclear risk’: report gave the impression of no dropouts or withdrawals, but this was not specifically stated. </p> <p>5. Selective reporting</p> <p>The possibility of selective outcome reporting.</p> <p>Grade: ’low risk’: reported outcomes prespecified in an available study protocol, or, if this is not available, published report includes all expected outcomes; ’high risk’: not all prespecified outcomes reported, reported using non‐prespecified subscales, reported incompletely or report fails to include a key outcome that would have been expected for such a study; ’unclear risk’: insufficient information. </p> <p>6. Funding bias</p> <p>Assessment of any possible funding bias.</p> <p>Grade: ’low risk’: reported no funding, funding from universities or public institutions; ’high risk’: funding from private investors, pharmaceutical companies or trial investigator employed by the pharmaceutical company; ’unclear risk’: insufficient information. </p> <p>7. Other bias</p> <p>Assessment of any possible sources of bias not addressed in domains 1 to 6.</p> <p>Grade: ’low risk’: report appears to be free of such biases; ’high risk’: at least one important bias is present that is related to study design, early stopping because of some data‐dependent process, extreme baseline imbalance, academic bias, claimed fraudulence or other problems; or ’unclear risk’: insufficient information or evidence that an identified problem will introduce bias. </p> </section> <section id="CD005370-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data (binary outcomes). These included: </p> <p>Primary outcomes:</p> <p> <ol id="CD005370-list-0005"> <li> <p>Overall mortality (longest follow‐up, regardless of the period of follow‐up)</p> </li> </ol> </p> <p>Secondary outcomes:</p> <p> <ol id="CD005370-list-0006"> <li> <p>Complications during the inpatient stay specific to the trial intervention</p> </li> <li> <p>Complications during the inpatient stay not specific to the trial intervention</p> </li> <li> <p>Complications specific to the trial intervention other than bleeding</p> </li> <li> <p>Bleeding events</p> </li> <li> <p>Incidence of surgical intervention</p> </li> <li> <p>Incidence of respiratory failure not present at admission</p> </li> <li> <p>Overall mortality among patients with severe sepsis and DIC</p> </li> </ol> </p> <p>We used the mean difference (MD) with a 95% confidence interval (CI), if data were continuous and measured in the same way between trials. </p> <p> <ol id="CD005370-list-0007"> <li> <p>Amount of red blood cells administered</p> </li> <li> <p>Severity of sepsis</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Length of stay in hospital</p> </li> <li> <p>Mean length of stay in the ICU</p> </li> </ol> </p> </section> <section id="CD005370-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <section id="CD005370-sec-0046"> <h5 class="title">Studies with multiple intervention groups</h5> <p>In accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005370-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [DOI: 10.1002/9780470712184] ">Higgins 2011</a>), for trials with two or more groups receiving different doses, we combined data for the primary and secondary outcomes. We excluded trials that only compared different doses of AT III and did not have a control group, with or without placebo. </p> </section> </section> <section id="CD005370-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of trials with missing data in order to retrieve the relevant information. For all included studies we noted levels of attrition and any exclusions. In case of missing data, we chose ’complete‐case analysis’ for our primary outcomes, which excludes from the analysis all participants with the outcome missing. </p> <p>Selective outcome reporting occurs when nonsignificant results are selectively withheld from publication (<a href="./references#CD005370-bbs2-0059" title="ChanAW , HróbjartssonA , HaahrMT , GøtzschePC , AltmanDG . Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004;291(20):2457‐65. [MEDLINE: 15161896] ">Chan 2004</a>), and is defined as the selection, on the basis of the results, of a subset of the original variables recorded for inclusion in publication of trials (<a href="./references#CD005370-bbs2-0065" title="HuttonJL , WilliamsonPR . Bias in meta‐analysis due to outcome variable selection within studies. Journal of the Royal Statistical Society Series2000;49(3):359‐70. [DOI: 10.1111/1467‐9876.00197] ">Hutton 2000</a>). The most important types of selective outcome reporting are: selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data and selective underreporting of data (<a href="./references#CD005370-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [DOI: 10.1002/9780470712184] ">Higgins 2011</a>). </p> </section> <section id="CD005370-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored heterogeneity using the I² statistic and Chi² test. An I² statistic above 50% represents substantial heterogeneity (<a href="./references#CD005370-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [DOI: 10.1002/9780470712184] ">Higgins 2011</a>). In case of I² statistic &gt; 0, we tried to determine the cause of heterogeneity by performing relevant subgroup analyses. We used the Chi² test to provide an indication of heterogeneity between studies, with a P value ≤ 0.1 considered significant. </p> </section> <section id="CD005370-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>Funding bias is related to the possible publication delay or discouragement of undesired results in trials sponsored by the industry (<a href="./references#CD005370-bbs2-0064" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. [DOI: 10.1002/9780470712184] ">Higgins 2011</a>). </p> </section> <section id="CD005370-sec-0050"> <h4 class="title">Data synthesis</h4> <section id="CD005370-sec-0051"> <h5 class="title">Data analysis</h5> <p>We used Review Manager 5 software (<a href="./references#CD005370-bbs2-0076" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a>). We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous variables and mean difference (MD) with CI for continuous outcomes. We used the Chi² test to provide an indication of heterogeneity between studies, with a P value &lt; 0.1 considered significant. The degree of heterogeneity observed in the results was quantified using the I² statistic, which can be interpreted as the proportion of the total variation observed between the studies that is attributable to differences between studies rather than to sampling error (<a href="./references#CD005370-bbs2-0063" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;15(11):1539‐58. [MEDLINE: 12111919] ">Higgins 2002</a>). An I² statistic &gt; 75% is considered as very heterogeneous. We used both a random‐effects model and a fixed‐effect model. If the I² statistic = 0% we only reported the results from the fixed‐effect model, and in the case of I² statistic &gt; 0% we reported only the results from the random‐effects model. </p> <section id="CD005370-sec-0052"> <h6 class="title"><i>Trial sequential analysis</i> </h6> <p>The risk of type 1 errors in meta‐analyses due to sparse data and repeated significance testing following updates with new trials remains a serious concern (<a href="./references#CD005370-bbs2-0058" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [MEDLINE: 18824466] ">Brok 2009</a>; <a href="./references#CD005370-bbs2-0080" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [MEDLINE: 18824467] ">Thorlund 2009</a>; <a href="./references#CD005370-bbs2-0081" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD005370-bbs2-0082" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;30(9):86. [MEDLINE: 20042080] ">Wetterslev 2009</a>). As a result, spurious P values due to systematic errors from trials with high risk of bias, outcome reporting bias, publication bias, early stopping for benefit and small trial bias may result in false conclusions. In a single trial, interim analysis increases the risk of type 1 errors. In order to avoid type 1 errors, group sequential monitoring boundaries (<a href="./references#CD005370-bbs2-0066" title="LanKKG , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. ">Lan 1983</a>) are used to decide whether a trial could be terminated early because of a sufficiently small P value; thus, the cumulative Z‐curve crosses the monitoring boundary. </p> <p>Equally, sequential monitoring boundaries can be applied to meta‐analyses and are labelled ’trial sequential monitoring boundaries’ (TSMBs). In ’trial sequential analysis’ (TSA), the addition of each new trial in a cumulative meta‐analysis is viewed as an interim meta‐analysis, which provides useful information on the need for additional trials (<a href="./references#CD005370-bbs2-0081" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> <p>It is appropriate and wise to adjust new meta‐analyses for multiple testing on accumulating data to control the overall type 1 error risk in cumulative meta‐analysis (<a href="./references#CD005370-bbs2-0073" title="PogueJM , YusufS . Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93. ">Pogue 1997</a>; <a href="./references#CD005370-bbs2-0074" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. ">Pogue 1998</a>; <a href="./references#CD005370-bbs2-0080" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [MEDLINE: 18824467] ">Thorlund 2009</a>; <a href="./references#CD005370-bbs2-0081" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> <p>When using TSA, if the cumulative Z‐curve crosses the boundary, there is an indication of a sufficient level of evidence having been reached, and as a consequence one may conclude that no further trials may be needed. However, evidence is insufficient to allow a conclusion if the Z‐curve does not cross the boundary or does not surpass the required information size. </p> <p>In order to construct the TSMBs, one needs a required information size which is calculated as the least number of participants required in a well‐powered single trial with low risk of bias (<a href="./references#CD005370-bbs2-0058" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [MEDLINE: 18824466] ">Brok 2009</a>; <a href="./references#CD005370-bbs2-0074" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. ">Pogue 1998</a>; <a href="./references#CD005370-bbs2-0081" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> <p>In this updated review, we adjusted the required information size for heterogeneity with the diversity adjustment factor (<a href="./references#CD005370-bbs2-0082" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;30(9):86. [MEDLINE: 20042080] ">Wetterslev 2009</a>). We applied TSA, as it prevents an increase in the risk of type 1 errors (20%). If the actual accrued information size was too small, we provided the required information size given the actual diversity (<a href="./references#CD005370-bbs2-0082" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;30(9):86. [MEDLINE: 20042080] ">Wetterslev 2009</a>) </p> </section> </section> </section> <section id="CD005370-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analyses:</p> <p> <ol id="CD005370-list-0008"> <li> <p>The effect of AT III in participants given heparin (all types and doses) versus participants not given heparin </p> </li> <li> <p>Comparing estimates of the pooled intervention effect in trials with low risk of bias to estimates from trials with high risk of bias (i.e. trials having at least one inadequate risk of bias component) </p> </li> <li> <p>Duration of drug administration (up to one week, more than one week)</p> </li> <li> <p>Completeness of follow‐up</p> </li> <li> <p>Comparing the pooled intervention effect in trials with a follow‐up that was longer than the median follow‐up with trials having a follow‐up equal to or shorter than the median follow‐up of trial participants. This was in order to detect a possible dependency of the estimate of intervention effect with length of follow‐up </p> </li> <li> <p>The effect of AT III in the trauma population</p> </li> <li> <p>The effect of AT III in obstetrics (eclampsia, pre‐eclampsia)</p> </li> <li> <p>The effect of AT III in paediatrics (we defined an age below 18 years for our inclusion criteria) </p> </li> <li> <p>The effect of AT III in sepsis and DIC</p> </li> </ol> </p> <p>If analyses of various subgroups were significant, we performed a test of interaction (<a href="./references#CD005370-bbs2-0056" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [MEDLINE: 12543843] ">Altman 2003</a>). We considered P values &lt; 0.05 as indicating significant interaction between the AT III effect and subgroup category. </p> <p>We included entire trials for subgroup analysis of trauma, obstetric, and paediatric participants. </p> </section> <section id="CD005370-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>We decided to carry out a sensitivity analysis on the results by applying fixed‐effect and random‐effects models to assess the impact of heterogeneity on our results. </p> <section id="CD005370-sec-0055"> <h5 class="title">Summary of findings</h5> <p>We used the principles of the GRADE approach to provide an overall assessment of the evidence relating to all of our outcomes. We constructed a 'Summary of findings' table using the GRADEpro software. As outcomes of public interest, we chose to present: mortality, bleeding events, incidence of respiratory failure not present at admission, duration of mechanical ventilation, length of stay in hospital, mean length of stay in ICU and overall mortality among patients with severe sepsis and DIC (see <a href="./full#CD005370-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005370-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005370-sec-0056"></div> <section id="CD005370-sec-0057"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD005370-sec-0119" title="">Characteristics of included studies</a>; <a href="./references#CD005370-sec-0120" title="">Characteristics of excluded studies</a>; Characteristics of studies awaiting classification; <a href="./references#CD005370-sec-0121" title="">Characteristics of ongoing studies</a> </p> <section id="CD005370-sec-0058"> <h4 class="title">Results of the search</h4> <p>Through electronic searches and from reading the references of potentially relevant articles, we identified 11287 publications on AT III (see <a href="#CD005370-fig-0002">Figure 2</a>). After reading the abstracts, we could directly exclude 11,173 publications. We retrieved 65 relevant publications for further assessment. From these 65 publications, we included 30 (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>), which randomized a total of 3933 participants. One trial (<a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>) was only published as an abstract and the data were so inadequate that they could not be used for further processing. Our analyses include a total of 3882 participants. The sample size varied from 16 to 2314 participants. We excluded 24 publications for the reasons detailed in the <a href="./references#CD005370-sec-0120" title="">Characteristics of excluded studies</a>. We found one ongoing trial (<a href="./references#CD005370-bbs2-0055" title="D'angeloA , ValsecchiL . A double‐blind trial of high‐dose antithrombin supplementation in early pre‐eclampsia. Thrombosis Research2005;115(Suppl 1):117. ">D'angelo 2005</a>) but no data were provided for this trial (see <a href="./references#CD005370-sec-0121" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD005370-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Flow" data-id="CD005370-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow</p> </div> </div> </div> <p>One trial was published in Russian only (<a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>), and one excluded trial was in German (Angstwurm 2009, a secondary publication of <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). We had these studies translated into English. Five trials had multiple full‐text publications or published post hoc subgroup analyses (<a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). </p> <p>In this updated review, we also included trials that were only published as abstracts in order to avoid publication bias (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>). </p> <section id="CD005370-sec-0059"> <h5 class="title">Types of participants</h5> <p>We classified two trials as obstetric studies (<a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>); four trials as paediatric trials (<a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>); and a further two trials as trauma studies (<a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). The remaining trials consisted of mixed populations of critically ill participants, mainly with sepsis. </p> </section> <section id="CD005370-sec-0060"> <h5 class="title">Types of interventions</h5> <p>The duration of the intervention varied from less than 24 hours to four weeks. Three trials had a median duration of AT III intervention that was longer than one week (<a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>). Follow‐up ranged from seven to 90 days. </p> </section> </section> <section id="CD005370-sec-0061"> <h4 class="title">Included studies</h4> <p>The 30 included trials were all published between 1985 and 2013. Five trials of AT III were multicentre trials (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). Five trials of AT III were multinational trials including Germany, Belgium, the Netherlands, Canada and the USA (<a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). One trial was carried out in 19 countries (<a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). Two trials did not state the location (<a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>). </p> <p>The 30 included trials involved a total of 3933 participants. The details of the included studies are provided in the table <a href="./references#CD005370-sec-0119" title="">Characteristics of included studies</a>. </p> <p>Fourteen trials recruited more male than female participants (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). One trial recruited only men (<a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>), two trials recruited only women (<a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>), six did not report the gender of the participants (<a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>) and two studies had more female than male participants (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>). The age of the participants included extends from the premature infant to the elderly intensive‐care participant. It therefore makes little sense to calculate the average age of the participants included. One trial however, excluded participants older than 75 (<a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>). </p> <p>Eighteen trials used an initial loading dose either based on weight (u/kg) or as a fixed dose (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). All trials except two (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>) stated the use of a maintenance dose. Nine trials used albumin as the control intervention (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>); two trials used fresh frozen plasma as the control intervention (<a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>); three trials only stated the use of an unknown placebo (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>). Nine trials used no placebo (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>). Four trials did not state which control they applied (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>). </p> </section> <section id="CD005370-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 24 randomized trials (<a href="./references#CD005370-bbs2-0031" title="AibikiM , FukuokaN , NishiyamaT , MaekawaS , ShirakawaY . Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. Shock2007;28(2):141‐7. [PUBMED: 17515857] ">Aibiki 2006</a>; <a href="./references#CD005370-bbs2-0032" title="DietrichW , BusleyR , SpannaglM , BraunS , SchusterT , LisonS . The influence of antithrombin substitution on heparin sensitivity and activation of hemostasis during coronary artery bypass graft surgery: a dose‐finding study. Anesthesia and Analgesia2013;116(6):1223‐30. [PUBMED: 23408673] ">Dietrich 2013</a>; <a href="./references#CD005370-bbs2-0033" title="DoiT , KozawaO , EnomotoY , OguraS . Analysis of the anti‐inflammatory effects of antithrombin III on human platelets. 7th Congress of the International Federation of Shock Societies ‐ 35th Annual Conference on Shock Miami Beach, FL United States2012;1:198. ">Doi 2012</a>; <a href="./references#CD005370-bbs2-0034" title="HoffmannJN , FertmannJM , IllnerW , ArbogastH , LandH , JauchK . High‐dose antithrombin can not improve kidney function despite improved graft perfusion in human kidney transplantation‐final results of a prospective, controlled trial. 23rd International Congress of the Transplantation Society, TTS 2010 Vancouver, BC Canada. 2010; Vol. 1:1882. ">Hoffmann 2010</a>; <a href="./references#CD005370-bbs2-0035" title="IliasW , ListW , DecruyenaereJ , LignianH , KnaubS , SchindelF , et al. Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Medicine2000;26(6):704‐15. [MEDLINE: 10945387] ">Ilias 2000</a>; <a href="./references#CD005370-bbs2-0036" title="JochumM . Influence of high‐dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Seminars in Hematology1995;32 Suppl 2(4):19‐32. [MEDLINE: 8821206] ">Jochum 1995</a>; <a href="./references#CD005370-bbs2-0037" title="KanbakM , OcB , SalmanMA , OcalT , OcM . Peroperative effects of fresh frozen plasma and antithrombin III on heparin sensitivity andcoagulation during nitroglycerine infusion in coronary artery bypass surgery. Blood Coagulation and Fibrinolysis2011;22(7):593‐9. [PUBMED: 21799398] ">Kanbak 2011</a>; <a href="./references#CD005370-bbs2-0038" title="KimKA , LimYY , KimSH , ParkJY . Bioequivalence of two intravenous formulations of antithrombin III: a two‐way crossover study in healthy Korean subjects. Clinical Therapeutics2013;35(11):1752‐61. [PUBMED: 24094463] ">Kim 2013</a>; <a href="./references#CD005370-bbs2-0039" title="KorningerC , KleptekoW , MiholicJ , SchwarzC , LechnerK . Randomized trial of antithrombin‐III versus placebo in patients undergoing peritoneo‐venous shunt operation. Thrombosis and Haemostasis1987;58(1):426. ">Korninger 1987</a>; <a href="./references#CD005370-bbs2-0040" title="LeitnerJM , FirbasC , MayrFB , ReiterRA , SteinlechnerB , JilmaB . Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clinical Pharmacology and Therapeutics2006;79(1):23‐34. [MEDLINE: 16413239] ">Leitner 2006</a>; <a href="./references#CD005370-bbs2-0041" title="MakiM , TeraoT , IkenoueT , TakemuraT , SekibaK , ShirakawaK , et al. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well‐controlled multicenter trial. Gynecology and Obstetric Investigation1987;23(4):230‐40. [MEDLINE: 3111953] ">Maki 1987</a>; <a href="./references#CD005370-bbs2-0042" title="MayumiT , SuzukiS , YamamotoT , IchikawaT , OnoderaM , TsuzukiM , et al. Levels of antithrombin activity after antithrombin administration indicate prognosis of septic DIC patients. Shock Society2011; Vol. 1:www.shocksociety.org/assets/docs/shock%202011%20oral%20abstracts.pdf. ">Mayumi 2011</a>; <a href="./references#CD005370-bbs2-0043" title="NeporadaE , TurundayevskayaO , VorobyevaN . Antithrombin III concentrate in comparison with FFP in patients with disseminated intravascular coagulation [КОНЦЕНТРАТ АНТИТРОМБИНА III В СРАВНЕНИИ СО СВЕЖЕЗАМОРОЖЕННОЙ ПЛАЗМОЙ ПРИ СИНДРОМЕ ДИССЕМИНИРОВАННОГО ВНУТРИСОСУДИСТОГО СВЕРТЫВАНИЯ]. Human Ecology2008;7:47‐51. ">Neporada 2008B</a>; <a href="./references#CD005370-bbs2-0044" title="NishiyamaT . Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesthesia and Analgesia2006;102(4):1007‐11. [MEDLINE: 16551889] ">Nishiyama 2006</a>; <a href="./references#CD005370-bbs2-0045" title="NCT01201070 . Trial registration. clinicaltrials.gov/ct2/show/NCT01201070 (accessed 21 April 2015). PaparellaD , RotunnoC , DePaloM , FinamoreS , GuidaP , RubinoG , et al. Antithrombin administration in patients with low antithrombin values after cardiac surgery: a randomized controlled trial. Annals of Thoracic Surgery2014;97(4):1207‐13. [PUBMED: 24507941] ">Paparella 2014</a>; <a href="./references#CD005370-bbs2-0046" title="PaternosterDM , DeFuscoD , TambuscioB . Treatment with antithrombin III (AT III) concentrate in pre‐eclampsia. International Journal of Gynaecology and Obstetrics2000;71(2):175‐6. [MEDLINE: 11064016] ">Paternoster 2000</a>; <a href="./references#CD005370-bbs2-0047" title="PaternosterDM , FantinatoS , ManganelliF . Efficacy of AT in pre‐eclampsia: a case‐control prospective trial. Thrombosis and Haemostasis2004;91(2):283‐9. [MEDLINE: 14961155] ">Paternoster 2004</a>; <a href="./references#CD005370-bbs2-0048" title="RanucciM , BaryshnikovaE , CrapelliGB , WoodwardMK , PaezA , PelisseroG . Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(5):1393‐9. [PUBMED: 23102903] ">Ranucci 2013</a>; <a href="./references#CD005370-bbs2-0049" title="SawamuraA , GandoS , HayakawaM , HoshinoH , KubotaN , SuganoM . Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clinical and Applied Thrombosis/Hemostasis2009;15(5):561‐6. [PUBMED: 18840625] ">Sawamura 2009</a>; <a href="./references#CD005370-bbs2-0050" title="SchererR , KabatnikM , ErhardJ , PetersJ . The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end‐stage chronic liver disease. Intensive Care Medicine1997;23(11):1150‐8. [MEDLINE: 9434921] ">Scherer 1997</a>; <a href="./references#CD005370-bbs2-0051" title="ShimadaM , MatsumataT , KamakuraT , HayashiH , UrataK , SugimachiK . Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates. Thrombosis Research1994;74(2):105‐14. [MEDLINE: 8029811] ">Shimada 1994</a>; <a href="./references#CD005370-bbs2-0052" title="TeraoT , KobayashiT , ImaiN , OdaH , KarasawaT . Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment. Asia‐Oceania Journal of Obstetrics and Gynaecology1988;15(1):25‐32. [MEDLINE: 2735838] ">Terao 1989</a>; <a href="./references#CD005370-bbs2-0053" title="ValsecchiL , D’AngeloA . High‐dose antithrombin supplementation in early pre‐eclampsia: a double‐blind, placebo controlled study (on behalf of the ATIII‐EPAS study group). Journal of Thrombosis and Haemostasis2009;7:297‐8. ">Valsecchi 2008</a>; <a href="./references#CD005370-bbs2-0054" title="VinazzerHA . Antithrombin III in shock and disseminate intravascular coagulation. Clinical and Applied Thrombosis/Hemostasis1995;1(1):62‐5. ">Vinazzer 1995</a>), for the reasons detailed in the <a href="./references#CD005370-sec-0120" title="">Characteristics of excluded studies</a>. </p> <section id="CD005370-sec-0063"> <h5 class="title">Ongoing studies</h5> <p>One trial is stated to be ongoing (<a href="./references#CD005370-bbs2-0055" title="D'angeloA , ValsecchiL . A double‐blind trial of high‐dose antithrombin supplementation in early pre‐eclampsia. Thrombosis Research2005;115(Suppl 1):117. ">D'angelo 2005</a>); see the <a href="./references#CD005370-sec-0121" title="">Characteristics of ongoing studies</a> </p> </section> <section id="CD005370-sec-0064"> <h5 class="title">Awaiting classification</h5> <p>No studies are awaiting classification.</p> </section> </section> </section> <section id="CD005370-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>All of the included studies were randomized controlled trials. However, the risk of bias of the included studies was high (<a href="#CD005370-fig-0003">Figure 3</a>). The trials often failed to report trial methodology in sufficient detail. See <a href="./references#CD005370-sec-0119" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD005370-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD005370-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <section id="CD005370-sec-0066"> <h4 class="title">Allocation</h4> <p>Generation of allocation sequence was adequately reported in 15 trials (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) (<a href="#CD005370-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD005370-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph summarized" data-id="CD005370-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph summarized</p> </div> </div> </div> <p>Allocation concealment was adequately reported in 14 trials (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) (<a href="#CD005370-fig-0004">Figure 4</a>). </p> </section> <section id="CD005370-sec-0067"> <h4 class="title">Blinding</h4> <p>Nine trials provided sufficient data to be categorized as double‐blinded (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). The remaining 21 trials were either open‐label or did not provide sufficient data on how the double‐blinding was achieved (<a href="#CD005370-fig-0004">Figure 4</a>). </p> </section> <section id="CD005370-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Two trials did not provide sufficient data (high risk) on follow‐up (<a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>). Six trials did not provide any data on follow‐up (unclear risk) (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>). Twenty‐two trials had adequate follow‐up (low risk) (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). </p> </section> <section id="CD005370-sec-0069"> <h4 class="title">Selective reporting</h4> <p>Ten trials provided adequate information to be classified as low‐risk trials (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). This was often due to supplementary information provided based on online registration, protocol availability or authors providing supplementary information while responding to our questions. </p> <p>Eighteen trials did not provide sufficient data on selective reporting (unclear risk) (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>). </p> <p>Three trials had substantial methodological shortcomings across multiple domains of bias (<a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>). </p> </section> <section id="CD005370-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Fourteen trials performed analysis according to the intention‐to‐treat (ITT) method or provided sufficient data for us to perform ITT analyses (<a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). </p> <p>Eight trials reported sample size calculations (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). </p> <p>Three trials (<a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>) reported receiving pharmaceutical company funding. </p> </section> </section> <section id="CD005370-sec-0071"> <h3 class="title" id="CD005370-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD005370-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD005370-sec-0072"> <h4 class="title">Primary outcomes</h4> </section> <section id="CD005370-sec-0073"> <h4 class="title">1. Overall mortality (longest follow‐up, regardless of the period of follow‐up)</h4> <p>Combining all trials showed no statistically significant effect of AT III on mortality, with a risk ratio (RR) of 0.95 (95% CI 0.88 to 1.03, I² statistic = 0%, P value = 0.91), based on data from 3882 participants in 29 trials. Results were analysed using a fixed‐effect model because heterogeneity was low. We downgraded the outcome from high to moderate quality of evidence because of 20 trials with high risk of bias. However, trial sequential analysis (TSA) led us to upgrade the overall assessment. Equally, for trials with only low risk of bias (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) we found no statistically significant effect; RR 0.96 (95% 0.88 to 1.04, I² statistic = 0%, fixed‐effect model, 9 trials, 2915 participants). Trials with only high risk of bias (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>) had a non‐significant RR of 0.94 (95% CI 0.77 to 1.14, I² statistic = 0%, fixed‐effect model, 20 trials, 967 participants) (<a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>). </p> <p>We conducted three subgroup analyses concerning the use of heparin (<a href="./references#CD005370-fig-0016" title="">Analysis 1.7</a>; <a href="./references#CD005370-fig-0017" title="">Analysis 1.8</a>; <a href="./references#CD005370-fig-0018" title="">Analysis 1.9</a>), but detected no statistically significant effects between the groups. </p> <p>We carried out 15 subgroup and sensitivity analyses in regard to our primary outcome, and found no statistically significant effect in any of them (<a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>; <a href="./references#CD005370-fig-0011" title="">Analysis 1.2</a>; <a href="./references#CD005370-fig-0012" title="">Analysis 1.3</a>; <a href="./references#CD005370-fig-0013" title="">Analysis 1.4</a>; <a href="./references#CD005370-fig-0014" title="">Analysis 1.5</a>; <a href="./references#CD005370-fig-0015" title="">Analysis 1.6</a>; <a href="./references#CD005370-fig-0016" title="">Analysis 1.7</a>; <a href="./references#CD005370-fig-0017" title="">Analysis 1.8</a>; <a href="./references#CD005370-fig-0018" title="">Analysis 1.9</a>; <a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>; <a href="#CD005370-tbl-0002">Table 1</a>). </p> <div class="table" id="CD005370-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis (Overall mortality)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT III</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on random sequence generation)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on allocation concealment)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.88 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.75 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on blinding)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.88 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.77 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on completeness of follow‐up)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.77 to 1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on ITT)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>705/1856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>736/1895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Low risk of bias trials (adequate random sequence generation): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (inadequate or unclear random sequence generation): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>. </p> <p><sup>2</sup>Low risk of bias trials (adequate allocation concealment): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (inadequate or unclear allocation concealment): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a> </p> <p><sup>3</sup>Low risk of bias trials (blinded): <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (not blinded or unclear blinding): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a> </p> <p><sup>4</sup>Low risk of bias trials (complete follow‐up): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>. High risk of bias trials (absence of complete follow‐up): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. </p> <p><sup>5</sup>Low risk of bias trials (ITT): <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (no ITT): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>. </p> </div> </div> </section> <section id="CD005370-sec-0074"> <h4 class="title">Secondary outcomes</h4> <p>Summarized in <a href="#CD005370-tbl-0003">Table 2</a> </p> <div class="table" id="CD005370-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes; refers to 'Data and analyses' 1.11; 1.12; 1.13; 1.14; 1.16; 1.19</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT III</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0020" title="">Analysis 1.11</a>: Intracranial bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.96 to 2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.51 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.83 to 1.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0021" title="">Analysis 1.12</a>: Renal failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.04 to 2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.08 to 6.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0022" title="">Analysis 1.13</a>: Complications other than bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.18 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.40 to1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.42 to 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>: Bleeding events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317/1492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201/1527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (1.35 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.57 (0.71 to 3.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (1.35 to 1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0025" title="">Analysis 1.16</a>: Incidence of surgical intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85 to 1.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0028" title="">Analysis 1.19</a>: Respiratory failure not present at admission </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115/1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137/1298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.77 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.45 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.76 to 1.14)</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD005370-sec-0075"> <h4 class="title">1. Complications during the inpatient stay specific to the trial intervention</h4> <p>Two trials with low risk of bias (<a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>) and one trial with high risk of bias (<a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>) demonstrated a statistically significant increase in complications specific to the trial intervention: RR 1.26 (95% CI 0.83 to 1.92, I² statistic = 9%, P value = 0.33), based on data from 2454 participants in the three trials. We analysed results using a random‐effects model. We downgraded the outcome from high to very low quality because of the small number of trials (<a href="./references#CD005370-fig-0020" title="">Analysis 1.11</a>) </p> </section> <section id="CD005370-sec-0076"> <h4 class="title">2. Complications during the inpatient stay not specific to the trial intervention</h4> <p>Two trials (<a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) did not reach statistical significance assessing complications not specific to the trial intervention: RR 0.71 (95% CI 0.08 to 6.11, I² statistic = 28%, P value = 0.24), based on data from 65 participants. We analysed results using a random‐effects model. We downgraded the outcome from high to very low quality because of the small number of trials (<a href="./references#CD005370-fig-0021" title="">Analysis 1.12</a>) </p> </section> <section id="CD005370-sec-0077"> <h4 class="title">3. Complications specific to the trial intervention other than bleeding</h4> <p>Three trials, one with low risk of bias (<a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>) and two with high risk of bias (<a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>), examined complications specific to the trial intervention other than bleeding: RR 0.72 (95% CI 0.42 to 1.25, I² statistic = 0%, P value = 0.95), based on data from 187 participants in the three trials. We analysed results using a fixed‐effect model. We downgraded the outcome from high to very low quality because of the small number of trials (<a href="./references#CD005370-fig-0022" title="">Analysis 1.13</a>) </p> </section> <section id="CD005370-sec-0078"> <h4 class="title">4. Bleeding events</h4> <p>Six trials with low risk of bias (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>) and five with high risk of bias (<a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>) demonstrated a statistically significant increase in bleeding events in the intervention group compared to the control group, with a RR of 1.58 (95% CI 1.35 to 1.84, I² statistic = 0%, P value = 0.57), based on data from 3019 participants in the 11 trials. We analysed results using a fixed‐effect model. We downgraded the outcome from high to moderate quality because of the proportion of trials with high risk of bias (<a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>) </p> </section> <section id="CD005370-sec-0079"> <h4 class="title">5. Amount of red blood cells administered</h4> <p>Four trials referred to the amount of red blood cells administered; one with low risk of bias (<a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>) and three with high risk of bias (<a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>) with a mean difference (MD) of 138.49 (95% CI ‐391.35 to 668.34, I² statistic = 88%, P value = 0.0001), based on data from 137 participants. We analysed results using a random‐effects model. We downgraded the outcome from high to very low quality because of the small number of trials, three of them with high risk of bias (<a href="./references#CD005370-fig-0024" title="">Analysis 1.15</a>) </p> </section> <section id="CD005370-sec-0080"> <h4 class="title">6. Incidence of surgical intervention</h4> <p>Three trials referred to the incidence of surgical intervention, all with low risk of bias (<a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) with a RR of 1.04 (95% CI 0.85 to 1.27, I² statistic = 0%, P value = 0.61), based on data from 103 participants. We analysed results using a fixed‐effect model. We downgraded the outcome from high to very low quality because of the small number of trials with few participants (<a href="./references#CD005370-fig-0025" title="">Analysis 1.16</a>) </p> </section> <section id="CD005370-sec-0081"> <h4 class="title">7. Severity of sepsis</h4> <p>Only <a href="./references#CD005370-fig-0026" title="">Analysis 1.17</a>, of the three different analyses (<a href="./references#CD005370-fig-0026" title="">Analysis 1.17</a>; <a href="./references#CD005370-fig-0027" title="">Analysis 1.18</a>; <a href="#CD005370-tbl-0004">Table 3</a>) reached statistical significance, with a MD of ‐1.24 (95% CI ‐2.18 to ‐0.29, I² statistic = 48%, P value = 0.015, random‐effects model, 3 trials, 156 participants) (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>) when examining the effect of AT III on various illness scores. Six trials provided data (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>). However, the trials that did provide data adequate for meta‐analysis were quite heterogenous in their application of various scores and their choice of time points. </p> <div class="table" id="CD005370-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Severity of sepsis III</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>AT III</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.66 to 0.26)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </div> </section> <section id="CD005370-sec-0082"> <h4 class="title">8. Incidence of respiratory failure not present at admission</h4> <p>Six trials examined the effect of AT III on the incidence of respiratory failure (not present at admission) (<a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). There was no statistically significant difference, with a RR of 0.93 (95% CI 0.76 to 1.14, I² statistic = 32%, P value = 0.22), based on data from 2591 participants in six trials. We analysed results using a random‐effects model. We downgraded the outcome from high to moderate quality because one trial contributed with the majority of patients (<a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>. It is considered to skew the finding; however, it is rated low risk of bias, and contributes a weighting of only 30.7%. A sensitivity analysis removing it from the plot eliminates all heterogeneity in that subgroup. </p> </section> <section id="CD005370-sec-0083"> <h4 class="title">9. Duration of mechanical ventilation</h4> <p>Three trials examined the effect of the trial intervention on duration of mechanical ventilation (<a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>). There was no statistically significant difference, with a MD of 2.20 (95% CI ‐1.21 to 5.60, I² statistic = 0%, P value = 0.89), based on data from 190 participants. We analysed results using a fixed‐effect model. We downgraded the outcome from high to very low quality of evidenc<i>e</i> because of the small number of trials, few participants and imprecision of results with a wide confidence interval. The mean duration of mechanical ventilation in the intervention group was 2.2 days more (1.21 fewer to 5.6 more). (<a href="./references#CD005370-fig-0029" title="">Analysis 1.20</a>). </p> </section> <section id="CD005370-sec-0084"> <h4 class="title">10. Length of stay in hospital</h4> <p>Four trials examined the intervention effect on the length of stay in hospital (<a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) with a MD of 1.10 (95% CI ‐7.16 to 9.36, I² statistic = 74%, P value = 0.009), based on data from 202 participants. We analysed results using a random‐effects model. We downgraded the outcome from high to very low quality of evidence because of the small number of trials, few participants and imprecision of results with a wide confidence interval. The mean length of stay in hospital in the intervention group was 1.1 days more (7.16 fewer to 9.36 more). (<a href="./references#CD005370-fig-0030" title="">Analysis 1.21</a>) </p> </section> <section id="CD005370-sec-0085"> <h4 class="title">11. Mean length of stay in the ICU</h4> <p>Three trials with low risk of bias (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) and four trials with high risk of bias (<a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>) examined the intervention effect on length of stay in the ICU. There was insufficient evidence to support any beneficial effect of the intervention, with a MD of 0.24 (95% CI ‐1.34 to 1.83, I² statistic = 0%, P value = 0.70), based on data from 376 participants. We analysed results using a fixed‐effect model. We downgraded the outcome from high to very low quality of evidence because of the small number of trials, most of them with high risk of bias. The mean length of stay in ICU in the intervention group was 0.24 days more (1.34 fewer to 1.83 more). (<a href="./references#CD005370-fig-0031" title="">Analysis 1.22</a>). </p> </section> <section id="CD005370-sec-0086"> <h4 class="title">12. Overall mortality among participants with severe sepsis and DIC</h4> <p>Twelve trials examined the intervention effect on mortality among participants with severe sepsis and disseminated intravascular coagulation (DIC) (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). The trials demonstrated a statistically significant decrease in mortality in favour of the trial intervention: RR 0.95 (95% CI 0.88 to 1.03, I² statistic = 0%, P value = 0.98), based on data from 2858 participants. We analysed results using a fixed‐effect model. We downgraded the outcome from high to very low quality of evidence, because of numerous trials with high risk of bias. The vast majority of trials were small and poorly described. </p> </section> <section id="CD005370-sec-0087"> <h4 class="title">Subjective overall quality‐of‐life assessment</h4> <p>Only one trial examined the intervention's effect on quality of life (<a href="./references#CD005370-bbs2-0077" title="RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Critical Care2002;Aug; 6(4):349‐56. [MEDLINE: 12225612] ">Rublee 2003</a>: based on data from <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). There was an objective assessment of physical performance and dependency, and a subjective overall quality‐of‐life assessment analysis. Neither assessment supported intervention with AT III, with a MD of ‐2.00, (95% CI ‐4.49 to 0.49, fixed‐effect model, 897 participants) and a MD of ‐2.00, (95% CI ‐5.01 to 1.01, fixed‐effect model, 897 participants) respectively, both rated at very low quality (<a href="#CD005370-tbl-0005">Table 4</a>; <a href="#CD005370-tbl-0006">Table 5</a>). </p> <div class="table" id="CD005370-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subjective overall quality of life assessment</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>At III</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00 (‐5.01 to 1.01)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </div> <div class="table" id="CD005370-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Objective assessment of physical performance and dependency (Karnofsky)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>AT III</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00 (‐4.49 to 0.49)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </div> </section> <section id="CD005370-sec-0088"> <h4 class="title">Subgroup and sensitivity analyses</h4> </section> <section id="CD005370-sec-0089"> <h4 class="title">The heparin issue</h4> <p>A detrimental interaction between AT III and heparin was suspected before the <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> trial, and we predefined use of AT III with and without heparin in the protocol for secondary analyses. However, the participants were not stratified according to heparin administration and the protocol allowed concomitant use of heparin by indication, after randomization to AT III or placebo. Even if the baseline comparison of participants allocated to AT III and placebo, in the subgroup without heparin, showed similar characteristics, the randomization is violated in the subgroup analysis. </p> <p>Pooling all trials with and without concomitant use of heparin, with the <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> trial as either a trial with concomitant use of heparin or as a trial without use of heparin, does not provide evidence of a statistically significant intervention effect of AT III (<a href="./references#CD005370-fig-0016" title="">Analysis 1.7</a>; <a href="./references#CD005370-fig-0017" title="">Analysis 1.8</a>). Even when splitting the <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> trial into two 'separate trials', with and without concomitant use of heparin, and pooling these results with the other trials, we found no statistically significant intervention effect of AT III in the subgroup of trials without adjuvant heparin administration (RR 0.95, 95% CI 0.88 to 1.03; I² statistic = 0%, fixed‐effects model, <a href="./references#CD005370-fig-0018" title="">Analysis 1.9</a>). However, splitting the <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> trial violates the randomization procedure. </p> </section> <section id="CD005370-sec-0090"> <h4 class="title">Trial sequential analysis</h4> <p>We conducted trial sequential analysis (TSA) of AT III versus control on longest follow‐up mortality (<a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>; <a href="#CD005370-fig-0005">Figure 5</a>). The TSA‐adjusted confidence interval for the meta‐analysis of the primary outcome with continuity correction for zero events trials (0.001 event in each arm) in a fixed‐effect model results in a RR of 0.95 (95% CI 0.88 to 1.03; I² statistic = 0%, Diversity D² = 0%). The point estimate of the potential intervention effect as suggested by the low risk of bias trials in the meta‐analysis of the effect of AT III on mortality is a relative risk reduction (RRR) of 5% and the low‐bias heterogeneity‐adjusted information size (LBHIS) calculated based on this intervention effect (with 80% power and alpha 0.05, assuming a double‐sided type I risk of 5% and a type II risk of 20%) is 23,634 participants (<a href="#CD005370-fig-0006">Figure 6</a>). With an accrued information size of 3882 participants and no boundaries crossed so far, only 16.43% of the required information size is actually available at this stage to reject or accept a 4% RRR for overall mortality. </p> <div class="figure" id="CD005370-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot, overall mortality regardless of follow‐up and bias Analysis 1.1" data-id="CD005370-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot, overall mortality regardless of follow‐up and bias Analysis 1.1</p> </div> </div> </div> <div class="figure" id="CD005370-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial sequential analysis of all trials with low risk of bias of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low‐bias heterogeneity‐adjusted information size of 23,634 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 16.43 % of the required information size has been reached so far." data-id="CD005370-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of all trials with low risk of bias of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low‐bias heterogeneity‐adjusted information size of 23,634 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 16.43 % of the required information size has been reached so far. </p> </div> </div> </div> <p>However, solid evidence may be obtained with fewer participants if eventually the cumulative meta‐analysis Z‐curve crosses the trial sequential monitoring boundary constructed for a required information size of 23,634 randomized participants. </p> <p>On the other hand, to demonstrate or reject an a priori anticipated intervention effect of a RRR of 10%, 5037 should be randomized. In this analysis, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority) (<a href="#CD005370-fig-0007">Figure 7</a>). As 3882 participants are included in the present meta‐analyses on mortality without the meta‐analysis becoming statistically significant and since the futility boundary is crossed, an intervention effect of 10% RRR or more on mortality is unlikely. </p> <div class="figure" id="CD005370-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA) of all trials of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 5037 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 3882." data-id="CD005370-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA) of all trials of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 5037 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 3882. </p> </div> </div> </div> <p>When carrying out the same TSA analyses as above for trials of sepsis and DIC only (<a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>) with an anticipated RRR of 10%, the required information size is 3794 participants without the meta‐analysis becoming statistically significant, and with the boundary for futility being crossed, thus indicating that a RRR of 10% is to be rejected. (<a href="#CD005370-fig-0008">Figure 8</a>) </p> <div class="figure" id="CD005370-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA) of all trials of sepsis and DIC examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 3794 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 2992." data-id="CD005370-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA) of all trials of sepsis and DIC examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 3794 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 2992. </p> </div> </div> </div> <p>TSA analysis based on a potential RRR of 5% as indicated by the meta‐analysis for studies on sepsis and DIC (<a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>) yields a LBHIS of 21,657 participants and with an accrued information size of 2992 participants and no boundaries being crossed so far, only 13.82% of the required information size is actually available (<a href="#CD005370-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD005370-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Trial sequential analysis of all trials of Sepsis and DIC with low risk of bias examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low bias heterogeneity adjusted information size of 21,657 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 13.82 % of the required information size has been reached so far." data-id="CD005370-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of all trials of Sepsis and DIC with low risk of bias examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low bias heterogeneity adjusted information size of 21,657 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 13.82 % of the required information size has been reached so far. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005370-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005370-sec-0091"></div> <section id="CD005370-sec-0092"> <h3 class="title" id="CD005370-sec-0092">Summary of main results</h3> <p>In this systematic review of 30 trials with 3933 participants we found no significant beneficial effect of AT III on mortality (<a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>). </p> <p>The analyses on mortality showed no heterogeneity and were robust when performing different subgroup analyses. Conversely, AT III increased the risk of bleeding (<a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>) and it appeared to improve only one of the reported severity of sepsis scores (multiple organ failure syndrome, MOFS) with limited data included in the analysis (inadequate power and precision) and remains a surrogate outcome (<a href="./references#CD005370-fig-0026" title="">Analysis 1.17</a>). None of the other secondary outcomes reached statistical significance. </p> <p>Neither the meta‐analysis nor the subgroup analyses demonstrated a statistically significant effect of AT III on mortality. However, this is not evidence of the absence of a beneficial effect, but the data suggest that a potentially beneficial effect of AT III must be at best modest compared to what had been expected. Trial sequential analysis added valuable information to the level of evidence and as such we are able to reject an intervention effect of 10% RRR or more for all trials, as well as trials including participants with sepsis and DIC. Additionally, based on the existing level of evidence from trials with low risk of bias, only 16.43% of the required information size is available to reject or accept a 5% RRR for overall mortality. </p> <section id="CD005370-sec-0093"> <h4 class="title">Subgroup analysis of duration of intervention and length of follow‐up</h4> <p>Based on follow‐up less than or longer than the median of all trials, we undertook a subgroup analysis to examine the intervention effect on mortality. However, there was no statistically significant association between follow‐up and mortality (see <a href="./references#CD005370-fig-0011" title="">Analysis 1.2</a>). The median follow‐up time was 32 days. </p> <p>We also examined the intervention effect based on the median duration of intervention being less than or longer than one week (<a href="./references#CD005370-fig-0012" title="">Analysis 1.3</a>). Only three trials with a total of 208 participants had a median duration of intervention longer than one week (<a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>). The current evidence does not support a longer duration of intervention. </p> </section> <section id="CD005370-sec-0094"> <h4 class="title">Subgroup analyses on paediatric, obstetric and trauma populations</h4> <p>Based on the existing data, we have to conclude that there is insufficient data to help us support or refute the use of AT III intervention among trauma, obstetric, or paediatric populations. </p> </section> <section id="CD005370-sec-0095"> <h4 class="title">Subgroup analyses regarding septic populations</h4> <p>Very few trials met our requirements in terms of trial intervention effect on various illness scores. We accepted the various definitions provided by the authors and undertook four different meta‐analyses. The participant numbers in these analyses ranged from 28 to 156, and only one meta‐analysis reached statistical significance (<a href="./references#CD005370-fig-0026" title="">Analysis 1.17</a>). The meta‐analyses examining the overall mortality in the septic population, based on 2918 participants, also failed to demonstrate a statistically significant reduction of mortality (<a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>). </p> </section> <section id="CD005370-sec-0096"> <h4 class="title">The heparin issue</h4> <p>We examined a potential detrimental interaction of AT III with heparin by carrying out three separate analyses pooling mortality data from trials with concomitant heparin use against those without (<a href="./references#CD005370-fig-0016" title="">Analysis 1.7</a>; <a href="./references#CD005370-fig-0017" title="">Analysis 1.8</a>; <a href="./references#CD005370-fig-0018" title="">Analysis 1.9</a>), while examining the impact of data from <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>. The latter trial was either defined as a trial with or without heparin use (<a href="./references#CD005370-fig-0016" title="">Analysis 1.7</a>; <a href="./references#CD005370-fig-0017" title="">Analysis 1.8</a>) and finally we chose to split data from <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> in order to examine the hypothesis. As such, this is to be considered a post hoc analysis violating the randomization procedure (<a href="./references#CD005370-fig-0018" title="">Analysis 1.9</a>). However, none of these analyses demonstrated any statistically significant interaction effects. </p> </section> </section> <section id="CD005370-sec-0097"> <h3 class="title" id="CD005370-sec-0097">Overall completeness and applicability of evidence</h3> <p>The authors of this updated review are confident that our search strategy obtained all available studies. We have contacted several authors. We identified two additional trials by Neporada et al. One was included (<a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>) and one excluded <a href="./references#CD005370-bbs2-0043" title="NeporadaE , TurundayevskayaO , VorobyevaN . Antithrombin III concentrate in comparison with FFP in patients with disseminated intravascular coagulation [КОНЦЕНТРАТ АНТИТРОМБИНА III В СРАВНЕНИИ СО СВЕЖЕЗАМОРОЖЕННОЙ ПЛАЗМОЙ ПРИ СИНДРОМЕ ДИССЕМИНИРОВАННОГО ВНУТРИСОСУДИСТОГО СВЕРТЫВАНИЯ]. Human Ecology2008;7:47‐51. ">Neporada 2008B</a>. </p> </section> <section id="CD005370-sec-0098"> <h3 class="title" id="CD005370-sec-0098">Quality of the evidence</h3> <p>The randomized controlled trial (RCT) is considered the most rigorous method of determining whether a cause‐effect relationship exists between an intervention and outcome. The strength of the RCT lies in the process of randomization. </p> <p>We rank the quality of findings from moderate to very low quality of evidence across the different outcomes. The main limiting factors were high risk of bias and small and poorly described trials. </p> <p>Nine trials were reported as being at completely low risk of bias (<a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>) (<a href="#CD005370-fig-0004">Figure 4</a>; <a href="#CD005370-fig-0003">Figure 3</a>). 16 of the of 30 included trials were at high risk or unclear risk of bias in random sequence generation (selection bias) (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>). Only one trial was registered on an available trial database (<a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>) Three trials had received funding from the pharmaceutical industry (<a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). </p> <p>The five trials (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>) only published as abstracts lack a great amount of valuable information with regard to methodology and outcomes, and we consequently rate them at high risk of bias. </p> <p>Application of the GRADE approach enables us to incorporate risk of bias, directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias. Based on these criteria, the quality of evidence in this review was very low and there was a high risk of bias. </p> </section> <section id="CD005370-sec-0099"> <h3 class="title" id="CD005370-sec-0099">Potential biases in the review process</h3> <p>Our systematic review has several potential limitations. As for all systematic reviews, our findings and interpretations are limited by the quality and quantity of the available evidence on the effects of AT III on mortality. We assessed the risk of bias of the included trials by using the published data, which ultimately may not reflect the truth. We tried to contacted all authors but only a few responded and provided further information. Three trials with 260 participants reported zero mortality in both trial groups (<a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>). </p> <p>We include five trials submitted only as abstracts in this updated review (<a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0005" title="BlauhutB , KramarH , VinazzerH , BergmannH . Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research1985;39(1):81‐9. [MEDLINE: 4035650] ">Blauhut 1985</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>). These abstracts lack important information. Nevertheless, a sensitivity analysis on the mortality data of only these trials yielded a RR of 0.91 (95% CI 0.55 to 1.52, I² statistic = 0%, fixed‐effect model). The result of the sensitivity analysis is highly comparable with and supportive of the overall mortality (<a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>). </p> <p>Due to a lack of convincing evidence in favour of AT III in settings without heparin, we chose to implement trial sequential analysis results, since the hypothesis of a beneficial effect of AT III in critically ill people still generates much attention. </p> <p>Although there was minimal heterogeneity among trial results on mortality, we are aware that we pooled very heterogeneous trials in terms of participants, settings, and treatment regimens. However, all the included conditions cause low levels of AT III, can result in DIC, and have similar inflammatory pathways. We therefore think that there is a biologically plausible reason to perform an inclusive meta‐analysis, which also considerably increases the generalizability and usefulness of the review. Furthermore, a broad meta‐analysis increases power, reduces the risk of erroneous conclusions, and facilitates exploratory analyses which can generate hypotheses for future research (for example, adjuvant heparin) (<a href="./references#CD005370-bbs2-0062" title="GotzschePC . Why we need a broad perspective on meta‐analysis. It may be crucially important for patients. BMJ2000;321(7261):585‐6. [MEDLINE: 10977820] ">Gotzsche 2000</a>). </p> <p>We have adhered to Cochrane methodology and applied additional statistical methods, such as TSA, to strengthen our conclusions and reduce the risk of random error. </p> </section> <section id="CD005370-sec-0100"> <h3 class="title" id="CD005370-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>The overall results of this updated systematic review are in accordance with the two previously published papers on the same topic, and only highlight the previously stated findings through inclusion of several additional studies. (<a href="./references#CD005370-bbs2-0086" title="AfshariA , WetterslevJ , BrokJ , MøllerA . Antithrombin III in critically ill patients: systematic review with meta‐analysis and trial sequential analysis. BMJ2007;335(7632):1248‐51. ">Afshari 2007</a>; <a href="./references#CD005370-bbs2-0087" title="AfshariA , WetterslevJ , BrokJ , MøllerA . Antithrombin III for critically ill patients. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD005370.pub2] ">Afshari 2008</a>) </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005370-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of AT III vs placebo or no intervention on number of bleeding events. The Diversity (D‐square) is 0%, the control event proportion is 13.2% and the required information size is estimated for an anticipated relative risk increase of 20% with a type 1 and 2 error risk of 5% and 20% respectively. The cumulative Z‐curve is breaking through the trial sequential monitoring boundary for harm suggesting, even though the required information size has not been reached, that AT III increases the number of bleeding events. The TSA‐adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85)." data-id="CD005370-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial sequential analysis of AT III vs placebo or no intervention on number of bleeding events. The Diversity (D‐square) is 0%, the control event proportion is 13.2% and the required information size is estimated for an anticipated relative risk increase of 20% with a type 1 and 2 error risk of 5% and 20% respectively. The cumulative Z‐curve is breaking through the trial sequential monitoring boundary for harm suggesting, even though the required information size has not been reached, that AT III increases the number of bleeding events. The TSA‐adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow" data-id="CD005370-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Flow</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD005370-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph summarized" data-id="CD005370-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph summarized</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot, overall mortality regardless of follow‐up and bias Analysis 1.1" data-id="CD005370-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot, overall mortality regardless of follow‐up and bias Analysis 1.1</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of all trials with low risk of bias of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low‐bias heterogeneity‐adjusted information size of 23,634 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 16.43 % of the required information size has been reached so far." data-id="CD005370-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial sequential analysis of all trials with low risk of bias of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low‐bias heterogeneity‐adjusted information size of 23,634 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 16.43 % of the required information size has been reached so far. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA) of all trials of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 5037 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 3882." data-id="CD005370-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA) of all trials of the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 5037 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 3882. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA) of all trials of sepsis and DIC examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 3794 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 2992." data-id="CD005370-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA) of all trials of sepsis and DIC examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the boundary constructed for an information size of 3794 in the meta‐analysis (full red line with open diamonds) with a RRR of 10% (α = 0.05) and a power of 80% (β = 0.20). However, the cumulative Z‐curve breaks through the boundary for futility (non‐superiority). The analysis therefore led to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials with a total number of accrued participants of 2992. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of all trials of Sepsis and DIC with low risk of bias examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low bias heterogeneity adjusted information size of 21,657 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 13.82 % of the required information size has been reached so far." data-id="CD005370-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Trial sequential analysis of all trials of Sepsis and DIC with low risk of bias examining the effect of AT III on mortality. Cumulative Z‐curve in blue does not cross the trial sequential monitoring boundary (full red line with open diamonds) constructed for a low bias heterogeneity adjusted information size of 21,657 participants corresponding to a RRR of 5% with an α = 0.05 and a power of 80% (β = 0.20). Only 13.82 % of the required information size has been reached so far. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 1 Mortality (subgroup analysis on bias risk)." data-id="CD005370-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 1 Mortality (subgroup analysis on bias risk). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 2 Overall mortality (subgroup analysis on median follow‐up)." data-id="CD005370-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 2 Overall mortality (subgroup analysis on median follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 3 Overall mortality (subgroup analysis on duration of intervention)." data-id="CD005370-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 3 Overall mortality (subgroup analysis on duration of intervention). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 4 Overall mortality (trauma)." data-id="CD005370-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 4 Overall mortality (trauma).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 5 Overall mortality (obstetrics)." data-id="CD005370-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 5 Overall mortality (obstetrics).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 6 Overall mortality (paediatrics)." data-id="CD005370-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 6 Overall mortality (paediatrics).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 7 Overall mortality (heparin; Warren 2001 as a trial with adjuvant heparin therapy)." data-id="CD005370-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 7 Overall mortality (heparin; Warren 2001 as a trial with adjuvant heparin therapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 8 Overall mortality (heparin; Warren 2001 as a trial without adjuvant heparin therapy)." data-id="CD005370-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 8 Overall mortality (heparin; Warren 2001 as a trial without adjuvant heparin therapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 9 Overall mortality (heparin; Warren 2001 data split based on heparin administration)." data-id="CD005370-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 9 Overall mortality (heparin; Warren 2001 data split based on heparin administration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 10 Overall mortality among patients with severe sepsis &amp; DIC." data-id="CD005370-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 10 Overall mortality among patients with severe sepsis &amp; DIC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 11 Complications during the inpatient stay specific to the trial intervention." data-id="CD005370-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 11 Complications during the inpatient stay specific to the trial intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 12 Complications during the inpatient stay not specific to the trial intervention." data-id="CD005370-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 12 Complications during the inpatient stay not specific to the trial intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 13 Complication specific to the trial intervention other than bleeding." data-id="CD005370-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 13 Complication specific to the trial intervention other than bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 14 Bleeding events." data-id="CD005370-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 14 Bleeding events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 15 Amount of red blood cells administered." data-id="CD005370-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 15 Amount of red blood cells administered.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 16 Incidence of surgical intervention." data-id="CD005370-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 16 Incidence of surgical intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 17 Severity of sepsis I." data-id="CD005370-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 17 Severity of sepsis I.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 18 Severity of sepsis II." data-id="CD005370-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 18 Severity of sepsis II.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 19 Incidence of respiratory failure not present at admission." data-id="CD005370-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 19 Incidence of respiratory failure not present at admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 20 Duration of mechanical ventilation." data-id="CD005370-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 20 Duration of mechanical ventilation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 21 Length of stay in hospital." data-id="CD005370-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 21 Length of stay in hospital.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005370-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/urn:x-wiley:14651858:media:CD005370:CD005370-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_t/tCD005370-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 AT III versus control, Outcome 22 Mean length of stay in ICU." data-id="CD005370-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 AT III versus control, Outcome 22 Mean length of stay in ICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/media/CDSR/CD005370/image_n/nCD005370-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005370-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AT III compared to control for critically ill patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Setting</b> : Worldwide<br/> <b>Intervention</b> : AT III<br/> <b>Comparison</b>: Control </p> <p><b>Patient or population</b>: critically ill participants </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with AT III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality (subgroup analysis on bias risk)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b><br/> (0.88 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3882<br/> (29 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>9 trials had low risk of bias, 20 trials high risk of bias.</p> <p>Trial sequential analysis (TSA) adjusted RR 0.95 (95% CI 0.87 to 1.04).</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (339 to 396) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>295 per 1000</b><br/> (273 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bleeding events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.58</b> (1.35 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3019<br/> (11 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6 trials had low risk of bias, 5 trials high risk of bias. Based on the TSA analysis, there seem to be evidence indicating that AT III increases risk of bleeding (<a href="./full#CD005370-fig-0001">Figure 1</a>). TSA adjusted meta‐analysis yields a RR of 1.85 (95% CI 1.35 to 1.85). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (339 to 396) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/> (87 to 119) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Incidence of respiratory failure not present at admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b><br/> (0.76 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2591<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5 trials had low risk of bias, 1 trial high risk of bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/> (80 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> (241 to 361) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 2.2 more (1.21 fewer to 5.6 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials had low risk of bias, 1 trial high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay in hospital</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean length of stay in hospital in the intervention group was 1.1 more (7.16 fewer to 9.36 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials had low risk of bias, 2 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of stay in ICU</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean length of stay in ICU in the intervention group was 0.24 more (1.34 fewer to 1.83 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials had low risk of bias, 4 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall mortality among patients with severe sepsis &amp; DIC</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> </p> <p>(0.88 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2858<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,8</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4 trials had low risk of bias, 8 trials high risk of bias</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b><br/> (407 to 476) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1000</b><br/> (345 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>With the exception of <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a> there was a high risk of bias in all trials. </p> <p><sup>2</sup>The entry refers to trials in <a href="./references#CD005370-fig-0010" title="">Analysis 1.1</a>. The outcome was downgraded two levels because of the substantial number of trials with high risk of bias but TSA led to an upgrade of one level to <i>moderate quality of evidence,</i> indicating no benefit for survival. The choice for this TSA upgrade was based on increased precision with continuity correction for zero event trials, adjustment for the risk of random error, a calculation of the required information size leading to rejection of an intervention effect of a RRR of 10% with a power of 80% in 30 randomized trials. </p> <p><sup>3</sup>The entry refers to trials in <a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>. The outcome was downgraded from high to <i>moderate quality of evidence</i> because majority of trials had high risk of bias. </p> <p><sup>4</sup>The entry refers to trials in <a href="./references#CD005370-fig-0028" title="">Analysis 1.19</a>. The outcome was downgraded from high to <i>moderate quality of evidence</i> since one large trial provided most of the data (<a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>). </p> <p><sup>5</sup>The entry refers to trials in <a href="./references#CD005370-fig-0029" title="">Analysis 1.20</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval. </p> <p><sup>6</sup>The entry refers to trials in <a href="./references#CD005370-fig-0030" title="">Analysis 1.21</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, high risk of bias, a small numbers of participants and imprecision of results with a wide confidence interval. </p> <p><sup>7</sup>The entry refers to trials in <a href="./references#CD005370-fig-0031" title="">Analysis 1.22</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of a small number of trials, most of them with high risk of bias. </p> <p><sup>8</sup>The entry refers to trials in <a href="./references#CD005370-fig-0019" title="">Analysis 1.10</a>. The outcome was downgraded from high to <i>very low quality of evidence</i> because of numerous trials with high risk of bias. The vast majority of trials were small and poorly described. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis (Overall mortality)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT III</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on random sequence generation)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on allocation concealment)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.88 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.75 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on blinding)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.88 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.77 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on completeness of follow‐up)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720/1915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>757/1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.77 to 1.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality (subgroup analysis on ITT)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>705/1856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>736/1895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.79 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I² = 0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Low risk of bias trials (adequate random sequence generation): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (inadequate or unclear random sequence generation): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>. </p> <p><sup>2</sup>Low risk of bias trials (adequate allocation concealment): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (inadequate or unclear allocation concealment): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a> </p> <p><sup>3</sup>Low risk of bias trials (blinded): <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (not blinded or unclear blinding): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a> </p> <p><sup>4</sup>Low risk of bias trials (complete follow‐up): <a href="./references#CD005370-bbs2-0002" title="BalkRA , BedrosianC , McCormickL , BaughmanJ , EiseleB , KeineckeHO , et al. Prospective double blind placebo‐controlled trial of ATIII substitution in sepsis. Intensive Care Medicine1995;21 Suppl 1:17. ">Balk 1995</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0023" title="PalaretiG , LegnaniC , CoccheriS , RidolfiL , BaudoF , CaimiTM , et al. Laboratory effects of antithrombin‐III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support ‐ a controlled, double‐blind, randomized multicenter study. Thrombosis and Haemostasis1995;73(6):1251. ">Palareti 1995</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>. High risk of bias trials (absence of complete follow‐up): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0028" title="Vorob'evaN , NeporadaE , TurundaevskaiaO , Mel'nikovaG . Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziologiia i Reanimatologiia2007;2:42‐4. [PUBMED: 17563999] ">Vorobyeva 2007</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. </p> <p><sup>5</sup>Low risk of bias trials (ITT): <a href="./references#CD005370-bbs2-0003" title="BaudoF , DeGasperiA , DeCataldoF , CaimiTM , CattaneoD , RedaelliR , et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thrombosis Research1992;68(4‐5):409‐16. [MEDLINE: 1290169] ">Baudo 1992</a>; <a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a>; <a href="./references#CD005370-bbs2-0008" title="FourrierF , ChopinC , HuartJJ , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [MEDLINE: 8365305] ">Fourrier 1993</a>; <a href="./references#CD005370-bbs2-0009" title="FuliaF , CordaroS , MeoP , GittoP , GittoE , TrimarchiG , et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?. Biology of the Neonate2003;83(1):1‐5. [MEDLINE: 12566675] ">Fulia 2003</a>; <a href="./references#CD005370-bbs2-0010" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):297. [PUBMED: 24342495] UMIN‐CTR Clinical Trial. Trial registration. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001064&amp;language=E (accessed 21 April 2015). [https://] ">Gando 2013</a>; <a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a>; <a href="./references#CD005370-bbs2-0013" title="HarperPL , WilliamsonL , ParkG , SmithJK , CarrellRW . A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine1991;1(2):121‐8. [MEDLINE: 9259838] ">Harper 1991</a>; <a href="./references#CD005370-bbs2-0014" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [MEDLINE: 15343012] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock1997;8(5):328‐34. [MEDLINE: 9361342] InthornD , HoffmannJN , HartlWH , MühlbayerD , JochumM . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock1998;10(2):90‐6. [MEDLINE: 9721974] ">Inthorn 1997</a>; <a href="./references#CD005370-bbs2-0016" title="LangleyPG , HughesRD , ForbesA , KeaysR , WilliamsR . Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology1993;17(3):326‐31. [MEDLINE: 8315261] ">Langely 1993</a>; <a href="./references#CD005370-bbs2-0018" title="MakiM , KobayashiT , TeraoT , IkenoueT , SatohK , NakabayashiM , et al. BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial. Thrombosis and Haemostasis2000;84(4):583‐90. [MEDLINE: 11057854] SameshimaH , KodamaY , IkenoueT , KajiwaraY . Antithrombin improves fetal condition in women with severe pre‐eclampsia before 32 weeks of gestation;a randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research2008;34(1):34–9. [PUBMED: 18226126] ">Maki 2000</a>; <a href="./references#CD005370-bbs2-0024" title="SchmidtB , GillieP , MitchellL , AndrewM , CacoC , RobertsR . A placebo‐controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;158(2):470‐6. [MEDLINE: 9700123] ">Schmidt 1998</a>; <a href="./references#CD005370-bbs2-0025" title="SchorrM , SiebeckM , ZugelN , WelckerK , Gippner‐SteppertC , CzwienzekE , et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation2000;30(4):359‐66. [MEDLINE: 10759886] ">Schorr 2000</a>; <a href="./references#CD005370-bbs2-0027" title="Smith‐ErichsenN , AasenAO , KongsgaardUE , BakkaA , BergenA , BjerkelundCE , et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care1996;7:291‐6. ">Smith‐Erichsen 1996</a>; <a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a>; <a href="./references#CD005370-bbs2-0030" title="WaydhasC , Nast‐KolbD , Gippner‐SteppertC , TrupkaA , PfundsteinC , SchweibererL , et al. High‐dose antithrombin III treatment of severely injured patients: results of a prospective study. Journal of Trauma, Injury, Infection and Critical Care1998;45(5):931‐40. [MEDLINE: 9820705] ">Waydhas 1998</a>. High risk of bias trials (no ITT): <a href="./references#CD005370-bbs2-0001" title="AlbertJ , BlomqvistH , GardlundB , JakobssonJ , SvenssonJ , BlombackM . Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia1992;36(8):745‐52. [MEDLINE: 1466208] ">Albert 1992</a>; <a href="./references#CD005370-bbs2-0004" title="BaudoF , CaimiTM , DeCataldoF , RavizzaA , ArlatiS , CasellaG , et al. Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double‐blind, randomized, multicenter study. Intensive Care Medicine1998;24(4):336‐42. [MEDLINE: 9609411] ">Baudo 1998</a>; <a href="./references#CD005370-bbs2-0006" title="Diaz‐CremadesJM , LorenzoR , SánchezM , MorenoMJ , AlsarMJ , BoschJM , et al. Use of antithrombin III in critical patients. Intensive Care Medicine1994;20(8):577‐80. [MEDLINE: 7706571] ">Diaz‐Cremades 1994</a>; <a href="./references#CD005370-bbs2-0011" title="GrenanderA , BredbackaS , RydvallA , ArochR , EdnerG , KoskinenLO , et al. Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology2001;13(1):49‐56. [MEDLINE: 11145479] ">Grenander 2001</a>; <a href="./references#CD005370-bbs2-0015" title="KobayashiT , TeraoT , IkenoueT , SameshimaH , NakabayashiM , KajiwaraY , et al. BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis2003;29(6):645‐52. [MEDLINE: 14719181] ">Kobayashi 2003</a>; <a href="./references#CD005370-bbs2-0017" title="LavrentievaA , KontakiotisT , BitzaniM , ParlapaniA , ThomareisO , ScourtisH , et al. The efficacy of antithrombin administration in the acute phase of burn injury.. Thrombosis and Haemostasis2008;100(2):286–90. [PUBMED: 18690349] ">Lavrentieva 2008</a>; <a href="./references#CD005370-bbs2-0019" title="MitchellL , AndrewM , HannaK , AbshireT , HaltonJ , WuJ , et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis2003;90(2):235‐44. [MEDLINE: 12888870] MitchellLG , AndrewM , HannaK , AbshireT , HaltonJ , AndersonR , et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase ‐ Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer2003;97(2):508‐16. [MEDLINE: 12518376] ">Mitchell 2003</a>; <a href="./references#CD005370-bbs2-0020" title="MunteanW , RosseggerH . Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis1989;62:288. ">Muntean 1989</a>; <a href="./references#CD005370-bbs2-0021" title="NeporadaE , VorobyevaN , NedashkovskyE . Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatologia2008;5:49‐54. ">Neporada 2008A</a>; <a href="./references#CD005370-bbs2-0022" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.. American Journal of Emergency Medicine2012;30(7):1219–23. [PUBMED: 22204993] ">Nishiyama 2011</a>; <a href="./references#CD005370-bbs2-0026" title="SchusterHP , EiseleB , KeineckeHO , HeinrichsH , MeschederA , KnaubS . S‐AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine1997;23 Suppl 1:76. ">Schuster 1997</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis (Overall mortality)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes; refers to 'Data and analyses' 1.11; 1.12; 1.13; 1.14; 1.16; 1.19</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT III</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control</p> <p>n/N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias trials</p> <p>RR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0020" title="">Analysis 1.11</a>: Intracranial bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/1228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.96 to 2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.51 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.83 to 1.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0021" title="">Analysis 1.12</a>: Renal failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 69.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.04 to 2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.08 to 6.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0022" title="">Analysis 1.13</a>: Complications other than bleeding </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.18 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.40 to1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.42 to 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0023" title="">Analysis 1.14</a>: Bleeding events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317/1492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201/1527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (1.35 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.57 (0.71 to 3.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58 (1.35 to 1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0025" title="">Analysis 1.16</a>: Incidence of surgical intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.85 to 1.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-fig-0028" title="">Analysis 1.19</a>: Respiratory failure not present at admission </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115/1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137/1298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.77 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.45 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.76 to 1.14)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes; refers to 'Data and analyses' 1.11; 1.12; 1.13; 1.14; 1.16; 1.19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Severity of sepsis III</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>AT III</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005370-bbs2-0007" title="EiseleB , LamyM , ThijsLG , KeineckeHO , SchusterHP , MatthiasFR , et al. Antithrombin III in patients with severe sepsis. A randomized, placebo‐controlled, double‐blind multicenter trial plus a meta‐analysis on all randomized, placebo‐controlled, double‐blind trials with antithrombin III in severe sepsis.. Intensive Care Medicine1998;24(7):663‐72. [MEDLINE: 9722035] ">Eisele 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.20 (‐0.66 to 0.26)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Severity of sepsis III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subjective overall quality of life assessment</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>At III</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00 (‐5.01 to 1.01)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subjective overall quality of life assessment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Objective assessment of physical performance and dependency (Karnofsky)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>AT III</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-bbs2-0029" title="AngstwurmM , HoffmannJ , OstermannH , FreyL , SpannaglM . Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin [Schwere sepsisund disseminierte intravasale erinnung. Substitution von antithrombin]. Anaesthesist2009;58(2):171–9. [PUBMED: 19189066] EidA , WiedermannCJ , KinasewitzGT . Early administration of high‐dose antithrombin in severe sepsis: single center results from the KyberSept‐trial. Anesthesia and Analgesia2008;107(5):1633‐8. [PUBMED: 18931224] GonanoC , SitzwohlC , MeitnerE , WeinstablC , KettnerSC . Four‐day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Critical Care2006;10(6):160. [PUBMED: 17107615] HoffmannJN , WiedermannCJ , JuersM , OstermannH , KienastJ , BriegelJ , et al. Benefit/risk profile of high‐dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis2006;95(5):850‐6. [MEDLINE: 16676077] KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [MEDLINE: 16409457] RubleeD , OpalSM , SchrammW , KeineckeHO , KnaubS . Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care2002;6(4):349‐56. [MEDLINE: 12225612] VanLeeuwenHJ , HeeziusEC , DallingaGM , VanStrijpJA , VerhoefJ , VanKesselKP . Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine2003;31(5):1359‐66. [MEDLINE: 12771603] WarrenBL , EidA , SingerP , PillaySS , CarlP , NovakI , et al. Caring for the critically ill patient. High‐dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA2001;286(15):1869‐78. [MEDLINE: 11597289] WiedermannCJ , HoffmannJN , JuersM , OstermannH , KienastJ , BriegelJ , et al. High‐dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine2006;34(2):285‐92. [MEDLINE: 16424704] ">Warren 2001</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>437</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00 (‐4.49 to 0.49)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Objective assessment of physical performance and dependency (Karnofsky)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/full#CD005370-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005370-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Severity of illness score</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>AT III</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Difference</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV, Fixed, 95% CI</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005370-bbs2-0012" title="HaireWD , RubyEI , StephensLC , ReedE , TarantoloSR , PavleticZS , et al. A prospective randomized double‐blind trial of antithrombin III concentrate in the treatment of multiple‐organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation1998;4(3):142‐50. [MEDLINE: 9923412] ">Haire 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.00 (‐20.40 to 0.40)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Subgroup analysis where only one trial had the relevant endpoints.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Severity of illness score</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/information#CD005370-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005370-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">AT III versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (subgroup analysis on bias risk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall mortality (subgroup analysis on median follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Mortality in trials with follow up less than median of all trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Mortality in trials with follow up longer than median of all trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall mortality (subgroup analysis on duration of intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Median duration of AT III intervention equal to or less than one week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Median duration of AT III intervention longer than one week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall mortality (trauma) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.81, 5.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.15, 77.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.72, 5.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall mortality (obstetrics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Overall maternal mortality, trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Overall foetal and neonatal mortality, trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall mortality (paediatrics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.73, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.54, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.56, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Overall mortality (heparin; Warren 2001 as a trial with adjuvant heparin therapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trials with complete or partially adjuvant heparin therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trials without adjuvant heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.71, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall mortality (heparin; Warren 2001 as a trial without adjuvant heparin therapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Trials with complete or partially adjuvant heparin therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Trials without adjuvant heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Overall mortality (heparin; Warren 2001 data split based on heparin administration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Trials with complete or partially adjuvant heparin therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Trials without adjuvant heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Overall mortality among patients with severe sepsis &amp; DIC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.64, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Complications during the inpatient stay specific to the trial intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.83, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.96, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.51, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Complications during the inpatient stay not specific to the trial intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.08, 6.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.04, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Complication specific to the trial intervention other than bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.42, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.35, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.35, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.71, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Amount of red blood cells administered <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>138.49 [‐391.35, 668.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐600.0 [‐899.18, ‐300.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>595.10 [‐287.14, 1477.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Incidence of surgical intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.85, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.85, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Severity of sepsis I <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.24 [‐2.18, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Final MOF score among survivors, trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.22, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Final MOF score among survivors, trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.92 [‐3.05, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Severity of sepsis II <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐4.36, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Final APACHE I &amp; II scores among survivors, trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐4.36, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Incidence of respiratory failure not present at admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.45, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Duration of mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐1.21, 5.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [‐1.69, 6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐4.68, 8.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Length of stay in hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐7.16, 9.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.67 [‐16.24, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.17 [2.75, 11.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Mean length of stay in ICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐1.34, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Trials with low bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐3.41, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Trials with high bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [‐1.20, 2.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">AT III versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005370.pub3/references#CD005370-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005370.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005370-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005370-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD005370-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pt#CD005370-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD005370-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005370\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005370\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005370\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005370\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005370\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005370.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005370.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005370.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005370.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005370.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728500346"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005370.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728500350"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005370.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5fb2dc59367',t:'MTc0MDcyODUwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 